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The molecular chaperone, heat shock protein 70 (Hsp70), is an important 
regulator of protein homeostasis that has roles in both primary protein folding and 
clearance of misfolded proteins. Several studies have suggested that it is the 
interaction between Hsp70 and a network of co-chaperones that might determine 
the fate Hsp70-bound substrates. For example, a complex formed between 
Hsp70 and the E3 ubiquitin ligase CHIP, is thought to guide substrates to the 
proteasome. However the mechanism governing how co-chaperones assemble 
on Hsp70 remains unresolved. We wanted to explore how interactions between 
Hsp70 and CHIP govern the ubiquitin-mediated degradation of chaperone 
substrates. Moreover, we hypothesize that chemical disruption of the Hsp70-
CHIP contact might decrease turnover of these substrates and, thereby, alter 
protein homeostasis.  
 
This thesis work involves the biophysical and structural characterization of the 
Hsp70-CHIP complex and synthesis of chemical probes that block CHIP binding 





tetratricopeptide repeat (TPR) domain of CHIP, along with an important 
secondary interaction in the charged coiled-coil domain govern binding of CHIP 
to Hsp70. In addition, we developed a dramatically improved synthesis of the 
promising natural product, spergualin, and created a collection of more potent 
and stable derivatives. We then showed that these compounds disrupt the 
Hsp70-CHIP interaction in vitro and in cells. Together, these findings provide a 
quantitative exploration of the CHIP-Hsp70 complex and the first set of chemical 
tools that can be used to regulate Hsp70 interactions with CHIP. We expect that 








Introduction: Protein-protein interactions as emerging drug targets 
 
1.1. Abstract 
Protein-protein interactions (PPIs) control the assembly of multi-protein 
complexes and, thus, these contacts have enormous potential as drug targets. 
However, the field has produced a mix of both exciting success stories and 
frustrating challenges, begging the question of how best to go after these difficult 
targets. Here, we review known examples and explore how the physical features 
of a PPI, such as its affinity, hotspots, off-rates, buried surface area and topology, 
may influence the chances of success in finding inhibitors. This analysis affirms 
that concise, tight binding PPIs are most amenable to inhibition. However, 
emerging technical methods are expanding the repertoire of “druggable” protein 
contacts and increasing the odds against difficult targets. In particular, natural 
product-like compound libraries, high throughput screens specifically designed 
for PPIs and approaches that favor discovery of allosteric inhibitors appear to be 
attractive routes. The first group of PPI inhibitors has entered clinical trials, 
further motivating the need to understand the challenges and opportunities in 
pursuing these types of targets. 
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1.2. Protein-protein interactions as novel targets in biology 
As revealed by proteomic and two-hybrid strategies, protein-protein interactions 
(PPIs) are extensive and ubiquitous in biology [1, 2]. PPIs hold together the key 
multi-protein complexes of the cell, guide sub-cellular trafficking and form the 
backbone of its major signaling pathways [3-6]. Accordingly, many PPIs are also 
potential therapeutic targets in disease [7, 8] and inhibiting PPIs has become an 
increasingly attractive goal for both drug discovery and the generation of new 
research probes [9].  
 
The last twenty years has witnessed considerable progress in the area of small 
molecule-based PPI inhibitors, with an explosion of literature reports and multiple 
PPI inhibitors entering clinical trials [10, 11]. For example, a search of PubChem 
for projects involving “protein-protein” interactions reveals more than 800 results. 
In these projects, research groups are employing a wide array of methodologies 
and often these methods are particularly suited for PPIs. At the same time, 
structural and computational biologists are becoming more adept at predicting 
PPIs and many groups are studying these interfaces to identify common 
topological features [12-15]. Clearly, this field is maturing rapidly and “tricks” are 
being developed to overcome the challenges associated with targeting PPIs. The 
prevailing attitude has changed considerably in the last two decades and PPIs 
are no longer considered uniformly “undruggable”. In this review, we 
 3 
retrospectively analyze a subset of successful cases to explore what lessons can 
be learned. 
 
1.3. Challenges of targeting protein-protein interactions 
1.3.1. Surface area 
Despite advances, small molecule inhibitors of PPIs remain a relatively daunting 
challenge, an idea clearly articulated in a number of recent reviews [16-23]. 
Informal polls of colleagues in the field suggest that successes are equally 
balanced with frustrations. There are several, well-described factors that 
contribute to this issue. Firstly, proteins that interact with other proteins typically 
do so using relatively large contact surfaces (1500 to 3000 Å2) [3]. This value is 
much larger than the average size of the contact area between a small molecule 
and protein target, which is estimated to be between 300 to 1000 Å2 [24]. This 
larger surface creates problems because molecules that target PPIs through 
competitive binding must typically have a high molecular weight to overcome the 
distributed free energy (ΔG) of the larger contact surface [16]. Accordingly, the 
resulting compounds may have difficulty fitting within the reported limits on the 
size of orally available drugs, as summarized by the Rule of Five (RO5) [25]. 
RO5 violations may shelve traditional drug leads, however a strict adherence to 
the RO5 for PPI programs seems likely to prove detrimental. In fact, the chemical 
properties of successful PPI antagonists have steadily shifted away from this 
benchmark [10]. Still, the sheer size of many PPIs poses an unavoidable 
 4 
challenge. One possible solution to this problem is that 'hotspots' within some 
PPI sites create a scenario in which a handful of amino acids contribute a 
disproportionate amount of the binding ΔG [26, 27]. Thus, targeting these specific 
regions typically has a more dramatic influence on the overall affinity and 
effectiveness of a small molecule. One of the earliest strategies to take 
advantage of this idea was the tethering method explored by Wells and 
colleagues [26]. In this approach, compound fragments are covalently directed to 
hotspots to maximize the chances of developing potent PPI inhibitors. More 
recently, fragment-based screening by mass spectrometry, crystallography and 
nuclear magnetic resonance (NMR) have become next-generation platforms for 
this type of discovery [28]. NMR, in particular, has proven a powerful method for 
finding building blocks that bind to topologically or energetically interesting sites 
on protein targets.  
 
1.3.2. Topology 
Another major issue related to PPI inhibition is that, compared to more traditional 
targets of antagonism, PPI partners often lack substantial grooves or deep 
pockets at their interacting surfaces [29]. For example, the Arora group reported 
an interesting study in which they analyzed PPI structures from the Protein Data 
Base (PDB), focusing on those PPIs involving a-helical interactions. They 
categorize these PPIs into examples with well-defined clefts and those with 
extended interfaces and use this information to suggest that PPIs with shallow 
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surfaces are less likely to be readily inhibited [30]. Regardless of the type of 
contact, screens for chemical PPI inhibitors often produce hits that are 
abnormally large, with complex topology, especially compared to traditional 
inhibitors [16, 25, 31]. These features can create synthetic challenges, in addition 
to possible issues with pharmacokinetics and solubility. As such, many groups 
have explored ways of improving chemical libraries to maximize the topological 
complexity of the library members and enrich for PPI inhibitors.  The goal in these 
approaches, such as diversity-oriented synthesis and others [32, 33], is to 
produce compounds able to match the topology of PPIs. These challenges have 
also sparked revitalized interest in natural products as another rich source of 
potential PPI inhibitors, given the high average complexity of these molecules 
[34]. Similarly, peptidomimetics, cyclic peptides and stapled peptides are being 
increasingly used to inhibit PPIs [35, 36]. These ligands mimic natural protein-
protein contacts by presenting multiple amino acid side chains from 
architecturally complex cores [37-41]. Finally, small molecule-protein hybrids 
have been developed to artificially increase apparent molecular mass and target 
the most difficult PPIs [42, 43].  
 
1.3.3. Promiscuity 
A related challenge to overcome in the search for PPI inhibitors is that a single 
contact surface on a protein can often have multiple binding partners [44] and, 
moreover, these partners can exchange in complex, dynamic equilibria [45]. 
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Thus, PPI inhibitors may have to contend with multiple protein competitors in the 
cell and, conversely, a single inhibitor may simultaneously disrupt multiple 
contacts, which could have unintended consequences on biology. Multi-protein 
complexes are often combinatorially assembled from a selection of possible 
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subunits in the cell. For example, certain chromatin-remodeling complexes and 
chaperone systems are built from components that bind in a mutually exclusive 
way [46, 47], allowing creation of complexes with distinct functions. This is the 
biological complexity that must be overcome when considering which PPI to 
target and what to expect from successful inhibition.  
 
1.4. Classes of protein-protein interaction inhibitors 
The first literary example of inhibiting a PPI came from a peptide mimic against 
the ribonucleotide reductase (RR) of herpes simplex virus type 1 (HSV1) in 1986. 
Two independent groups showed that a nonapeptide representing the C-terminus 
of an essential subunit in the HSV1 RR holoenzyme was sufficient to inhibit RR 
activity [48, 49]. Since then, the field has produced a large and ever increasing 
number of successful inhibitors [16, 17, 23]. With that growing list of examples, 
can we begin to “bin” PPIs into categories that are predictive of their relative 
chances of success? Similarly, can this retrospective analysis reveal common 
topological features that make PPIs more or less challenging?  
 
As one way to approach these questions, we selected 19 published chemical 
inhibitors of PPIs (which represents a subset of the total) and ranked these in 
terms of buried surface area and affinity (Figure 1.1; Table 1.1). Using cutoffs 
intended to reveal whether any properties are common to clustered systems, we 
generated four categories of PPIs. These categories are colloquially termed 
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“Tight and Narrow”, “Tight and Wide”, “Loose and Narrow” and “Loose and 
Wide”. These terms are defined based on the size of the buried surface area and 
the affinity of the PPI. For surface area, narrow was defined as less than 2500 
Å2, while wide was greater than 2500 Å2.  Likewise, the affinity of the contact was 
separated into tight (Kd less than 200 nM) or loose (Kd greater than 200 nM).  
 
1.4.1. Protein-protein interactions "Tight and Narrow"    
To date, this category of PPI has proven most amenable to inhibition, producing 
the most potent inhibitors and a large number of examples (Figure 1.2). The 
reasons for this relative success could be due to the fact that the physical 
features shared by members of this class are most similar to traditional, enzyme 
targets. These PPIs are those with high affinity encompassed in a relatively small 
surface area. They also typically have deep pockets that are engaged by less 
than five major amino acids that contribute a majority of the binding ΔG. Because 
of these concise features, some of the strategies used in typical drug discovery 
campaigns, such as high throughput screening (HTS) and structure-based 
design, can be readily employed to target these PPIs. However, a number of PPI-
specific methods have also been developed and some of those methods have 
subsequently been used to tackle more challenging targets.  
 
In 1997, a group at Hoffmann-La Roche rationally designed a low micromolar 
inhibitor of the interaction between interleukin 2 (IL-2) and the IL-2α receptor [50]. 
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Based off of this molecule, researchers at Sunesis Pharmaceuticals developed 
the mid-nanomolar antagonist SP4206 8 (Ki= 60 nM). The Sunesis group 
developed structure-activity relationships (SAR) by NMR, combined with 
tethering, to incrementally build this molecule [51]. An instructive idea that arose 
from that work came from the fact that the structural characterization of these 
compounds was originally based on their direct binding to IL-2. It was only after 
the structure of the IL-
2/IL2Rα complex was 
solved that it became 
apparent that SP4206 
bound to the same 
residues of IL-2 that are 
used to bind the IL-2Rα. 
Moreover, SP4206 
induced a conformational 
change at the PPI surface by interacting with residues that were shown by 
alanine scanning to encompass a disproportionate amount of binding ΔG (e.g. a 
“hotspot”) [52]. Thus, this early example of a successful PPI inhibitor uncovered a 
number of principles that became repetitive themes in other systems; namely, 
compound-induced allostery and hotspot binding. 
 
Small-molecule inhibitors of the PPI between p53 and mouse double minute 2 
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(MDM2) were identified based on the results of a high throughput screen. As was 
observed in the case of IL2, these cis-imidazolines, termed nutlins, were shown 
to occupy the same binding pocket on MDM2 that is critical for binding to p53 
[53]. Nutlin-3 9 was shown to have mid-nanomolar (~70 nM) and enantioselective 
activity towards the p53-MDM2 complex, leading to an accumulation of p53 and 
subsequent tumor suppression [54]. Nutlin-3 is currently in phase I clinical trial for 
the treatment of retinoblastoma, illustrating the promise of PPI inhibitors as drugs 
and solidifying the idea that surface mimicry and hotspot binding are key tools for 
targeting this class of PPI. The concept of mimicking the natural interactions was 
also used in a parallel strategy to inhibit p53-MDM2. This strategy was inspired 
by the natural product spiro(oxindole-3,3'-pyrrilodine) scaffold, which mimics the 
indole ring of Trp23 in p53 that binds to a deep, hydrophobic cavity in MDM2 [55]. 
This rational-design approach, coupled with medicinal chemistry efforts yielded 
MI-63, which was further developed to MI-219 10 to improve its pharmacokinetic 
profile. MI-219 shows low nanomolar (~5 nM) inhibition of complex formation with 
sub-micromolar (0.4 to 0.8 μM) IC50 values for tumor growth inhibition [56]. The 
Wang group has pioneered additional rational design approaches in which they 
start with the structure of the PPI, perform alanine scans to identify possible 
hotspots and then design peptidomimetics and synthetic scaffolds that are 
intended to disrupt critical contacts [57, 58]. These examples are clear cases in 
which the structure of the PPI can be used to launch inhibitor programs. 
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Another key lesson is illustrated by the work of Abbott investigators in their 
search for inhibitors of B-cell lymphoma 2 (Bcl-2). Fesik and colleagues 
employed fragment screening by NMR, followed by extensive NMR-structure-
guided medicinal chemistry to developed ABT-737 12, which binds the anti-
apoptotic molecules Bcl-XL, Bcl-2, and Bcl-W and prevents their association with 
pro-apoptotic proteins BAD and BAX (Ki >1 nM) [59]. This compound, and its 
orally bioavailable derivative ABT-263, shows anti-proliferative activity against a 
number of cancer cell lines, as well as anti-tumor activity in xenograft animal 
models [60]. ABT-263 is currently in phase I/II trial as a single agent for relapsed 
or refractory lymphoid malignancies, and in phase II trial for lymphatic leukemia 
in combination with the antibody therapeutic rituximab. This work was some of 
the first to document how NMR could be used as a primary discovery tool for 
identifying and elaborating drug leads [61]. More broadly, NMR-based design of 
PPI inhibitors, often combined with some form of HTS, has been particularly 
successful in this category of interactions, as illustrated by examples in the 
Runx1-CBFb [62] and MLL [63]. 
 
 
1.4.2. Protein-protein interactions "Tight and Wide"     
Some PPIs involve extensive and often convoluted or discontinuous interaction 
surfaces, creating contacts with large buried contact areas and tight affinities. 
These features can create special difficulties in developing small-molecule 
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inhibitors because of the slow off rates and the large surfaces to overcome. Still, 
a number of successful examples have been reported and a review of these 
cases suggests some methodologies with potentially far-reaching utility. 
 
Of the 15 enzymes encoded in the human immunodeficiency virus (HIV) genome, 
three are essential homo- or pseudo-dimers [64]. Two of these proteins, HIV-1 
protease (HIVp) and reverse transcriptase (RT) have been successfully targeted 
with small-molecule inhibitors. The HIVp dimer has an interacting face with over 
3,000 Å2 of buried surface area [65] and a Kd value in the low nanomolar range 
[66]. Similarly, the HIV-1 RT multimer interface buries 2,730 Å2 [67] with a Kd of 
400 pM [68]. In the late 1990s, two groups identified HIVp dimerization inhibitors 
by screening natural products (1, 2) [69, 70]. Likewise, exploration of non-
nucleoside inhibitors of HIV-1 RT revealed 5, which was subsequently shown to 
have anti-dimerization activity [71, 72]. These findings support the idea that 
topologically complex natural products are suitable scaffolds for inhibiting even 
complex and large PPIs. To further exemplify this idea, the interaction surface 
between β-catenin and Tcf/LEF family members is also particularly large (> 3000 
Å2), making it another difficult target [73]. Yet, 6 was identified in a natural 
product screen that relied on measuring binding of Tcf4 to β-catenin [74]. 
However, natural products are not exclusive in their ability to inhibit these types 
of interactions. Recently, an in silico screen revealed 7, a simpler structure that is 
predicted to bind to a hotspot region and inhibit the β-catenin-Tcf4 interaction 
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[75]. Additional structural information will be needed to fully understand the 
binding mode and mechanistic basis for these activities, but the findings suggest 
that topologically complex chemical libraries may be good starting points for 
identifying PPI inhibitors. 
 
The inducible isoform of nitric oxide synthase (iNOS) has been implicated in 
inflammatory and autoimmune diseases [76], while the endothelial isoform plays 
a vital role in vascular homeostasis [77]. In an effort to identify selective inhibitors 
of iNOS, McMillan et al. (2000) conducted an in vitro screen against iNOS 
enzyme activity using a compound library based off of a pyrimidine-imidazole 
core [78]. This screen resulted in no active compounds, but a cell-based screen 
against nitric oxide production yielded the potent inhibitor 3. The compound was 
shown to have a high affinity for the iNOS monomer and, upon binding, it 
allosterically inhibited subsequent dimerization, explaining why the original in 
vitro screen against the pre-formed iNOS dimer produced no inhibitors. This 
example nicely illustrates a growing realization that allostery and allosteric 
mechanisms are powerful tools in targeting larger PPIs [12, 79]. Moreover, this 
study illustrates how dynamics can have a large impact on success in HTS-
based PPI campaigns. Only when iNOS was allowed to sample both monomeric 
and dimeric structures were allosteric inhibitors uncovered.  
 
Other interesting examples of this class are found in inhibitors of the c-Myc/Max 
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dimer, the CD40 ligand (CD40L) trimer, and the eukaryotic translation initiation 
factors (eIF) eIF4E and eIF4G. A hurdle to small-molecule inhibition of c-
Myc/Max dimerization is the vast increase in dimer stabilization in the presence 
of DNA [80]. To circumvent this issue, the Berg group developed a clever HTS 
approach in which c-Myc/Max binding to a fluorophore-labeled oligonucleotide 
was measured, revealing Mycros 1 and 2 as micromolar inhibitors [81]. This 
study nicely leveraged known biophysical features of the PPI to design a screen 
especially targeting a key aspect of the complex. Similarly, identifying inhibitors of 
CD40L trimerization are also difficult, given the tight affinity of this complex. Yet, 
a direct binding assay was used to produce BIO8898 4, a small molecule that 
populates a deep, allosteric pocket between two subunits of the trimer [82]. 
Binding by BIO8898 distorts the interface enough to prevent binding of CD40L to 
the CD40 receptor. This is a more subtle form of inhibition than seen in previous 
studies of the homologous TNFα, where an inhibitor was found that completely 
ejected one subunit from the trimer [83]. These examples suggest that even 
challenging PPIs can sometimes be amenable to HTS approaches, using 
methodologies, such as AlphaLisa, fluorescence and luminescence 
complementation, ELISA, SPR and FRET [84-87], and the resulting compounds, 
if the screen is designed carefully, can access unexpected and interesting 
molecular mechanisms. This concept is further re-enforced by work from the 
Wagner group, in which they developed a high-throughput fluorescence 
polarization screen against the initiation factor eIF4E using a peptide from the 
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binding motif of eIF4G [88]. This screen revealed the inhibitor 4EGI-1 that 
disrupts full-length eIF4G binding, and interestingly, clears the path for natural 
modulators of translation (4E-BP) to interact and thereby inhibit translation. 
Together, these examples demonstrate the diversity of solutions to the problem 
of blocking large, tight interactions. 
 
As illustrated by the examples above, this class of PPIs has been successfully 
targeted and the resulting compounds access interesting mechanisms. Another 
example was provided by the Neubig group, in which they used a flow cytometry 
protein interaction assay (FCPIA) to target regulators of G-protein signaling 
(RGS). They identified CCG-4986, which inhibits the RGS4-Gα PPI by covalent 
modification of a cysteine residue adjacent to the interaction surface [89]. This 
example highlights a growing resurgence of covalent modifiers as probes and 
drugs [90]. Covalent modifiers might be particularly attractive for PPIs because 
irreversible binding can be used to overcome problems of weak interactions and 
shallow binding sites. 
 
Amyloids are ordered protein aggregates defined by a characteristic appearance 
by electron microscopy, affinity for the dye, congo red, and large contact 
interfaces between monomers [91]. The interface challenge is exacerbated by 
the repetitive structure of amyloids, involving thousands of monomer interactions 
and thousands of cumulative Å2 of buried surface area. Amyloids underlie a 
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number of neurodegenerative disorders and other diseases of protein misfolding 
[92], so inhibitors of amyloid PPIs are of medical interest. Numerous small 
molecules with tight affinity for amyloids have been described, some based on 
synthetic scaffolds and others based on peptidomimetics [91, 93, 94]. Some of 
these molecules have even advanced to clinical trials in Alzheimerʼs disease. 
Interestingly, these compounds typically have good Kd values, yet their ability to 
block PPIs between amyloid-forming monomers (IC50) is typically 10- to 1000-fold 
worse. The disconnect between these values is thought to arise from compound 
binding being insufficient to fully block the large amyloid surfaces, which often 
lack clear “hotspots”. In 2004, it was discovered that hybrids between congo red 
and the FK506-binding protein (FKBP) created bifunctional inhibitors that better 
matched the size and complexity of the amyloid surface, producing inhibitors with 
nanomolar IC50 values [42]. Interestingly, increasing the size of the FKBP portion 
enhanced the apparent IC50 of the hybrids, suggesting that larger surfaces were 
more effective inhibitors [95]. Another clever solution to this problem can be 
found in anti-amyloid strategies using compounds that dissolve pre-formed 
aggregates by allostery [96]. Thus, even for some of the most extreme PPIs, 
allostery and other mechanisms can be used to inhibit their formation. 
 
1.4.3. Protein-protein interactions "Loose and Narrow"    
PPIs within this category are characterized by weak (Kd > 200 nM) binding but 
relatively small contact areas. Because these interactions are typically transient, 
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it is not unusual for the surfaces to be shared by multiple partners. These 
hurdles, often coupled to a lack of structural data and relatively shallow binding 
pockets, make these interactions especially challenging targets (Figure 1.2).  
However, in one example of a successful approach, the N-terminal β-propeller 
domain (TD) of the clathrin heavy chain was targeted. Clathrin heavy chain 
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serves as a central interacting hub for accessory proteins in the endocytic 
pathway [97]. Two molecules termed pitstops, one from a naphthalimide core 15 
and the other from rhodanine 16 were identified in an ELISA-based high-
throughput screen [98]. These compounds were shown to compete with 
accessory proteins for binding to a common site on the clathrin TD, limiting 
endocytosis and thereby inhibiting viral entry. Despite this success, general 
strategies for targeting this class are not yet clear. 
 
In another interesting example that illustrates the challenges in this type of PPI, 
the Mapp group identified compounds that inhibit transcriptional activation within 
the activator complex [99]. These authors recognized that a conserved structural 
element of natural activation domains is that they are amphipathic. They 
displayed polar functionality from an isoxazolidine core and, indeed, found that 
the only apparent requirement for creating artificial activators was that the 
molecule needed to be amphipathic [100, 101]. This relatively loose structural 
constraint suggests that the strategies for optimizing inhibitors of this type of PPI 
will be substantially different than for other types of targets.  
 
 
1.4.4. Protein-protein interactions “Loose and Wide”   
At the extreme end of PPIs are the contacts defined by large surface areas and 
weak affinities. To our knowledge, few potent inhibitors of contacts within this 
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category have been described and these targets remain a particularly challenging 
area. Yet, very recent evidence suggests that inhibition at this level is possible. 
The interaction between the small GTP-binding protein Ras and its guanidine 
nucleotide exchange factor (GEF) SOS1 spans approximately 3600 Å2 [102] and 
Ras binds to the catalytic site of SOS1 with an affinity in the low micromolar 
range [103], placing this PPI square within the “loose and wide” category. Recent 
work has produced a stapled peptide [104] and a small molecule (19) [105] 
capable of inhibiting this interaction both in vitro and in cells.  Other biological 
examples of these PPIs are plentiful in the literature, especially in the area of 
GPCR clustering, cell-cell interactions and carbohydrate-protein interactions 
[106], creating a need for PPI inhibitors. 
 
1.5. Advancing protein-protein interaction inhibitors in difficult systems 
As evident from visually placing PPIs into quadrants (Figure 1.1), some systems, 
especially weaker interactions and those that make contacts over a wide area, 
remain notoriously resistant to inhibition. This challenge is further evident by the 
large differences in the average potency values for inhibitors targeting the 
different classes. On average, compounds that inhibit “Tight and Narrow” PPIs 
have 10-fold better potency than those targeting “Loose and Narrow” contacts 
(Figure 2). Many of these resistant systems have commonalities among them, 
such as limited structural information, transient and weak contacts and 
promiscuous binding interfaces. To further illustrate these ideas and highlight 
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methodologies developed to specifically address these challenges, we focus on 
the heat shock protein 70 (Hsp70) and heat shock protein 90 (Hsp90) systems 
for further discussion. Hsp70 and Hsp90 are molecular chaperones that each 
form multi-protein complexes with important roles in protein folding and 
stabilization. Moreover, there is compelling evidence, in both cases, to suggest 
that targeting PPIs in the Hsp70 and Hsp90 complexes may be an effective 
therapeutic strategy in cancer and neurodegeneration [107-111]. These systems 
also provide a convenient model for these discussions because the PPIs inherent 
in Hsp70 and Hsp90 complexes provide examples of nearly every type of PPI 
category.  
 
1.5.1. Heat shock protein 70  
Hsp70 plays important roles in normal protein homeostasis and it is implicated in 
several disease states, such as cancer, neurodegeneration, and amyloidosis 
[107, 108, 112, 113]. The protein consists of two domains, a nucleotide binding 
domain (NBD) that hydrolyzes ATP and a substrate-binding domain (SBD) that 
binds to exposed hydrophobic regions of polypeptides. NMR-based fragment 
screens conducted by the biotechnology company, Vernalis, have shown that the 
ATP-binding site of Hsp70 is not particularly amenable to discovery of selective 
or potent inhibitors [114]. Thus, the PPIs between Hsp70 and its numerous co-
chaperones have become attractive alternatives [107, 108, 115]. There are three 
main classes of proteins that bind to Hsp70s. The Hsp40 (or DnaJ) superfamily is 
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characterized by a conserved J-domain that binds to Hsp70 and stimulates its 
ATPase activity [116]. This stimulation of ATP turnover promotes tight binding of 
substrates in the SBD via a conformational change. Nucleotide exchange factors 
(NEFs) bind Hsp70 and facilitate ADP release, helping to release substrates. 
And, finally, a family of tetratricopeptide repeat (TPR) domain-containing co-
chaperones binds to the SBD, helping to arbitrate the fate of Hsp70-bound 
substrates [113]. Thus, either promoting or inhibiting PPIs between Hsp70 and its 
co-chaperones can modulate the biology of the system [107, 108].  
 
The J domain of the prokaryotic Hsp40, DnaJ, binds to the Hsp70, DnaK, across 
a largely polar interface located between the NBD and SBD [117]. The Kd of this 
interaction is weak (> 1 µM) and a structure of the auxilin J-domain fused to 
mammalian Hsp70 suggests a relatively modest interaction surface (1028 Å2) 
[118]. Structures of Hsp70 bound by NEFs suggest a larger (2800 Å2) interaction, 
with much higher affinity (30 nM) [119]. Finally, the TPR domain interaction with 
Hsp70 is approximately 1 µM [120] and occurs over an area of 1330 Å2, based 
on a crystal structure of a representative TPR domain with the C-terminus of 
Hsp70 [121]. Based on genetic studies, each of these interfaces is attractive as a 
therapeutic target.  
 
Our group has become particularly interested in targeting the Hsp70-Hsp40 
interaction because of the importance of the contact in chaperone biology [116]. 
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Recent work by the Zuiderweg group has shown that the prokaryotic Hsp70-
Hsp40 contact is largely polar, with a complex and shallow topology [117]. Thus, 
we originally considered it unlikely that a screen for direct (e.g. competitive) 
inhibitors of the direct PPI would be fruitful, given the weak binding of the two 
partners. Accordingly, we pursued a different strategy, termed “gray box 
screening”. In this method, the ATPase activity of Hsp70 is stimulated by 
reconstituting its complex with an Hsp40 in vitro. Any compounds that disrupt 
Hsp40-stimulated ATP turnover would be identified as a “hit” in the screen. This 
approach is termed gray box screening because it has some features in common 
with “black box” screens, in which whole cells or animals are used as the target. 
In cell-based screens, the physiological relevance of the platform is high, but 
target identification is a challenging task. In the gray box approach, some of the 
natural complexity of the system is mimicked by reconstitution of the multi-protein 
system. This approach has been used to identify a number of inhibitors of the 
Hsp70-Hsp40 complex, some of which bind directly at the PPI interface [122] and 
others that bind distal, allosteric sites [123]. For example, the flavonoid myricetin 
14 was found to bind an unanticipated site in the NBD, about 30 Å from the 
Hsp70-Hsp40 interface, trapping a conformation that is not able to interact with 
Hsp40 [123]. Interestingly, the binding site for myricetin is not apparent in the 
crystal structures of the Hsp70 NBD, suggesting that dynamic movements in this 
region are required to open the compound-binding site [124]. Because this 
screening approach is amenable to HTS in low volume, large numbers of 
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compounds can be screened [125, 126]. This strategy might be applicable in 
other systems involving weak interactions, especially those in which non-enzyme 
partners allosterically modify the activity of a core enzyme component. 
 
The Hsp70-TPR protein interaction, while also weak, sits at a critical point in 
Hsp70 biology. TPR proteins are thought to facilitate triage decisions for client 
proteins of Hsp70 [115, 127, 128], assisting in either folding or degradation of 
these clients. Therefore, this PPI is of unique interest to chemical biologists who 
seek to attain fine control of the Hsp70 machinery. However, to date, no inhibitors 
of the Hsp70-TPR domain interaction have been described in the literature, 
highlighting the challenge that this interface may pose. This idea will be further 
explored in the subsequent chapters. 
 
The tighter Hsp70-NEF interaction has been targeted using a “black box” high 
throughput screen. From a cell-based assay against p53-mediated apoptosis, 
PES 13 was identified as a small-molecule that decreases tumor cell viability 
[129]. In follow-up studies, PES appears to block the binding of Hsp70 to the M 
isoform of bcl-2 associated anthanogene 1 (BAG-1), a NEF for Hsp70. These 
findings (along with the nutlin work described above) suggest that phenotypic 
screens can sometimes reveal PPI inhibitors, even if the target PPI is relatively 
large. One power of these methods is that the target PPI is allowed to undergo its 
natural dynamics, often providing unanticipated mechanisms of inhibition. The 
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challenge is that the mechanism of inhibition is not clear until follow-up studies 
are performed. 
 
1.5.2. Heat shock protein 90    
The Hsp70 and Hsp90 systems are linked through a shared TPR-domain co-
chaperone, HOP (Hsp70-Hsp90 organizing protein) [130]. And like Hsp70, Hsp90 
is an abundant molecular chaperone that relies on a network of these co-
chaperones for its activity [131]. Under both stress and normal conditions, Hsp90 
regulates the stability and maturation of over 200 client proteins, many of which 
either harbor mutations or are over-expressed in cancers [132]. In fact, inhibitors 
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of the ATPase activity of Hsp90, which bind to the N-terminal ATP-binding 
pocket, have been extensively explored and some of these have advanced to 
clinical trials as anti-cancer agents [133]. These inhibitors bind classically defined 
pockets and do not appear to directly impact co-chaperone binding. However, 
one drawback of these molecules is that they elicit a heat shock response, 
through activation of heat shock factor 1 (HSF1) [134]. This cytoprotective 
response has the potential to undermine the anti-proliferative effects of Hsp90 
inhibition. These issues have driven interest in targeting the C-terminal ATP-
binding site [135] and, importantly for this review, PPIs between Hsp90 and its 
co-chaperones.  
 
Hsp90 interacts with the important co-chaperones Aha1, cdc37, p23 and a 
number of TPR-domain proteins [130]. These interactions tune the ATPase 
activity of Hsp90 and these PPIs are being recognized as potential drug targets 
[111]. The TPR-Hsp90 interaction surface resembles that in the TPR-Hsp70 
system, being relatively weak but narrow. Cdc37 interacts with relatively poor 
affinity (2.5 μM) [136] to Hsp90, burying 1600 Å2 of solvent exposed surface 
area, while Aha1 binds across a very large, polar surface of Hsp90 [137] with 
moderate affinity (0.6 μM) [138]. Thus, like the Hsp70 system, this multi-protein 
complex has a wide range of affinities and surface areas.  
 
An investigation into how the natural product, celastrol 17 inhibited Hsp90 and 
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elicited a heat-shock response initially revealed that the compound reduced the 
interaction between Hsp90 and the cancer associated co-chaperone cdc37 [139]. 
Upon further analysis, it was revealed that celastrol covalently binds to the Hsp90 
co-chaperone, cdc37 [140]. Recently, a molecule 18 based off of another natural 
product, Sansalvamide A, was reported to bind to Hsp90 and inhibit the 
interaction of TPR domain-containing co-chaperones [141]. Other inhibitors of the 
Hsp90-TPR interaction have also been identified by HTS approaches [141, 142]. 
Thus, like in the Hsp70 system, “biology-driven” HTS was employed as a 
successful strategy to identify PPIs inhibitors in the Hsp90 system and natural 
products were common hits. 
 
1.6. Analysis and prospectus 
Protein-protein interactions are the “glue” that drives biology, especially in the 
context of multi-protein complexes, signaling pathways and subcellular trafficking. 
To take advantage of these opportunities, a growing urgency has emerged 
around inhibiting PPIs. In addition, a number of successes in the field of chemical 
inhibitors of PPIs, including initiation of multiple clinical trials, have provided a 
strong motivator for continued experimental focus. 
 
What can be learned from analyzing prior success and failures in targeting PPIs 
with small molecules? One over-whelming observation is that PPI inhibitors are 
not as hard to find as one might expect. Many straightforward HTS methods have 
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successfully produced micromolar and nanomolar inhibitors, especially of concise 
PPIs. Many of the most successful PPI inhibitors have taken advantage of 
hotspots that effectively reduce large, flat surfaces to more manageable targets. 
Another common solution is found in compounds that bind allosteric sites to 
modify PPIs, as was the case with the IL2 inhibitors and myricetin in the Hsp70 
system. These compounds utilized well-defined pockets to enact global changes 
at either adjacent (in the case of IL2) or distal (in the case of Hsp70) PPI 
contacts. Allostery can work over substantial distances [143] and through multiple 
components of a multi-protein complex, further suggesting that even topologically 
complex surfaces can be impacted. Also, allosteric sites can be versatile tools, 
sometimes allowing switching between agonism and antagonism [122, 144]. 
Finally, it seems possible that many of the allosteric sites found in PPI projects 
might represent the binding sites for natural ligands, such as secondary 
metabolites. Despite this progress, clear challenges remain. Can the 
pharmacokinetic and synthetic challenges of larger molecules be solved? How 
does one purposefully search for allosteric regulators? 
 
What methods are best for identifying PPI inhibitors? The answer to this question 
appears to be dependent on the type of PPI, the specific biological goals and 
other factors. Rational design approaches have succeeded in cases of both large 
surface areas (as is the case with stapled peptides) and concise PPIs (as was 
seen with inhibitors of p53-MDM2). NMR is likely to continue to be a powerful 
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method for discovery of PPI inhibitors because it combines structural insights 
with fragment-based approaches (as was seen in the case of Bcl-2). Finally, 
unbiased HTS methods, especially gray box screening and cell-based methods, 
have proven surprisingly fruitful in the search for PPI inhibitors of many types. 
These methods seem particularly attractive in systems involving large contact 
surfaces, owing to their propensity to find unanticipated allosteric sites. Thus, the 
workhorse for drug discovery in this difficult chemical space is likely to continue 
to be HTS-based methodology, especially for binding partners where there exists 
a limited amount of structural information.  
 
What do these studies mean for understanding the biology and “druggability” of 
multi-protein complexes? Many, if not all, biological processes are dependent on 
the function of multi-protein complexes [145-147]. These processes emerge from 
the coordinated activity of multiple enzyme and non-enzyme components. In a 
post-genomic world, medicinal chemists are viewing drug targets within the 
context of the multi-protein pathways and networks in which they act. This more 
sophisticated view includes a greater number of possible PPI targets, further 





1. Stelzl, U., et al., A Human Protein-Protein Interaction Network: A 
Resource for Annotating the Proteome. Cell, 2005. 122(6): p. 957-968. 
2. Rual, J.-F., et al., Towards a proteome-scale map of the human protein-
protein interaction network. Nature, 2005. 437(7062): p. 1173-1178. 
3. Jones, S. and J.M. Thornton, Principles of protein-protein interactions. 
Proceedings of the National Academy of Sciences of the United States of 
America, 1996. 93(1): p. 13-20. 
4. Gavin, A.C., et al., Functional organization of the yeast proteome by 
systematic analysis of protein complexes. Nature, 2002. 415(6868): p. 
141-147. 
5. Ryan, D.P. and J.M. Matthews, Protein-protein interactions in human 
disease. Current Opinion in Structural Biology, 2005. 15(4): p. 441-446. 
6. Kuriyan, J. and D. Eisenberg, The origin of protein interactions and 
allostery in colocalization. Nature, 2007. 450(7172): p. 983-990. 
7. Balch, W.E. and J.R. Yates, Application of Mass Spectrometry to Study 
Proteomics and Interactomics in Cystic Fibrosis. Cystic Fibrosis: 
Diagnosis and Protocols, Vol II: Methods and Resources to Understand 
Cystic Fibrosis, 2011. 742: p. 227-247. 
8. Vidal, M., M. Cusick, and A.-L. Barabasi, Interactome Networks and 
Human Disease. Cell, 2011. 144(6): p. 986-998. 
9. Arkin, M., Protein-protein interactions and cancer: small molecules going 
in for the kill. Current Opinion in Chemical Biology, 2005. 9(3): p. 317-324. 
10. Morelli, X., R. Bourgeas, and P. Roche, Chemical and structural lessons 
from recent successes in protein-protein interaction inhibition (2P2I). 
Current Opinion in Chemical Biology, 2011. 15(4): p. 475-481. 
11. Thangudu, R.R., et al., Modulating Protein‚ÄìProtein Interactions with 
Small Molecules: The Importance of Binding Hotspots. Journal of 
Molecular Biology, 2012. 415(2): p. 443-453. 
12. Reynolds, K., R. McLaughlin, and R. Ranganathan, Hot Spots for 
Allosteric Regulation on Protein Surfaces. Cell, 2011. 147(7): p. 1564-
1575. 
13. Yang, C.-Y. and S. Wang, Computational Analysis of Protein Hotspots. 
ACS Medicinal Chemistry Letters, 2010. 1(3): p. 125-129. 
14. Geppert, T., et al., Context-Based Identification of Protein-Protein 
Interfaces and ‚ÄúHot-Spot‚Äù Residues. Chemistry &amp; Biology, 2011. 
18(3): p. 344-353. 
15. Reichmann, D., et al., The modular architecture of protein-protein binding 
interfaces. Proceedings of the National Academy of Sciences of the United 
States of America, 2005. 102(1): p. 57-62. 
16. Wells, J.A. and C.L. McClendon, Reaching for high-hanging fruit in drug 
discovery at protein-protein interfaces. Nature, 2007. 450(7172): p. 1001-
1009. 
 30 
17. Keskin, O., et al., Principles of protein-protein interactions: What are the 
preferred ways for proteins to interact? Chemical Reviews, 2008. 108(4): 
p. 1225-1244. 
18. Berg, T., Modulation of Protein–Protein Interactions with Small Organic 
Molecules. Angewandte Chemie International Edition, 2003. 42(22): p. 
2462-2481. 
19. Veselovsky, A.V., et al., Protein–protein interactions: mechanisms and 
modification by drugs. Journal of Molecular Recognition, 2002. 15(6): p. 
405-422. 
20. Gordo, S. and E. Giralt, Knitting and untying the protein network: 
Modulation of protein ensembles as a therapeutic strategy. Protein 
Science, 2009. 18(3): p. 481-493. 
21. Meireles, L.M.C. and G. Mustata, Discovery of Modulators of Protein-
Protein Interactions: Current Approaches and Limitations. Current Topics 
in Medicinal Chemistry, 2011. 11(3): p. 248-257. 
22. Toogood, P.L., Inhibition of protein-protein association by small molecules: 
Approaches and progress. Journal of Medicinal Chemistry, 2002. 45(8): p. 
1543-1558. 
23. Arkin, M.R. and A. Whitty, The road less traveled: modulating signal 
transduction enzymes by inhibiting their protein-protein interactions. 
Current Opinion in Chemical Biology, 2009. 13(3): p. 284-290. 
24. Cheng, A.C., et al., Structure-based maximal affinity model predicts small-
molecule druggability. Nature Biotechnology, 2007. 25(1): p. 71-75. 
25. Lipinski, C.A., et al., Experimental and computational approaches to 
estimate solubility and permeability in drug discovery and development 
settings. Advanced Drug Delivery Reviews, 2001. 46(1-3): p. 3-26. 
26. Clackson, T. and J. Wells, A hot spot of binding energy in a hormone-
receptor interface. Science, 1995. 267(5196): p. 383-386. 
27. Erlanson, D.A., J.A. Wells, and A.C. Braisted, TETHERING: Fragment-
Based Drug Discovery. Annual Review of Biophysics and Biomolecular 
Structure, 2004. 33(1): p. 199-223. 
28. Valkov, E., et al., Targeting Protein–Protein Interactions and Fragment-
Based Drug Discovery Fragment-Based Drug Discovery and X-Ray 
Crystallography. 2012, Springer Berlin / Heidelberg. p. 145-179. 
29. Hopkins, A.L. and C.R. Groom, The druggable genome. Nature Reviews 
Drug Discovery, 2002. 1(9): p. 727-730. 
30. Jochim, A.L. and P.S. Arora, Systematic Analysis of Helical Protein 
Interfaces Reveals Targets for Synthetic Inhibitors. Acs Chemical Biology, 
2010. 5(10): p. 919-923. 
31. Walters, W.P., A. Murcko, and M.A. Murcko, Recognizing molecules with 
drug-like properties. Current Opinion in Chemical Biology, 1999. 3(4): p. 
384-387. 
32. Schreiber, S.L., Target-Oriented and Diversity-Oriented Organic Synthesis 
in Drug Discovery. Science, 2000. 287(5460): p. 1964-1969. 
 31 
33. Xu, Y., et al., A credit-card library approach for disrupting protein-protein 
interactions. Bioorganic &amp; Medicinal Chemistry, 2006. 14(8): p. 2660-
2673. 
34. Reayi, A. and P. Arya, Natural product-like chemical space: search for 
chemical dissectors of macromolecular interactions. Current Opinion in 
Chemical Biology, 2005. 9(3): p. 240-247. 
35. Woodman, R., et al., Design and Validation of a Neutral Protein Scaffold 
for the Presentation of Peptide Aptamers. Journal of Molecular Biology, 
2005. 352(5): p. 1118-1133. 
36. Kritzer, J.A., et al., Miniature Protein Inhibitors of the p53–hDM2 
Interaction. ChemBioChem, 2006. 7(1): p. 29-31. 
37. Verdine, G.L., et al., Chapter one - Stapled Peptides for Intracellular Drug 
Targets, in Methods in Enzymology. 2012, Academic Press. p. 3-33. 
38. Walensky, L.D., et al., Activation of Apoptosis in Vivo by a Hydrocarbon-
Stapled BH3 Helix. Science, 2004. 305(5689): p. 1466-1470. 
39. Zhang, H., et al., A Cell-penetrating Helical Peptide as a Potential HIV-1 
Inhibitor. Journal of Molecular Biology, 2008. 378(3): p. 565-580. 
40. Horswill, A.R., S.N. Savinov, and S.J. Benkovic, A systematic method for 
identifying small-molecule modulators of protein‚Äìprotein interactions. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2004. 101(44): p. 15591-15596. 
41. Ruvo, M., et al., Branched Peptides for the Modulation of Protein-Protein 
Interactions: More Arms are Better than One? Current Medicinal 
Chemistry, 2011. 18(16): p. 2429-2437. 
42. Gestwicki, J.E., G.R. Crabtree, and I.A. Graef, Harnessing Chaperones to 
Generate Small-Molecule Inhibitors of Amyloid √ü Aggregation. Science, 
2004. 306(5697): p. 865-869. 
43. Gestwicki, J.E. and P.S. Marinec, Chemical control over protein-protein 
interactions: Beyond inhibitors. Combinatorial Chemistry & High 
Throughput Screening, 2007. 10(8): p. 667-675. 
44. DeLano, W.L., et al., Convergent solutions to binding at a protein-protein 
interface. Science, 2000. 287(5456): p. 1279-1283. 
45. Sprinzak, E., Y. Altuvia, and H. Margalit, Characterization and prediction of 
protein-protein interactions within and between complexes. Proceedings of 
the National Academy of Sciences of the United States of America, 2006. 
103(40): p. 14718-14723. 
46. Lessard, J.A. and G.R. Crabtree, Chromatin Regulatory Mechanisms in 
Pluripotency, in Annual Review of Cell and Developmental Biology, Vol 
26, R.G.L.L.R. Schekman, Editor. 2010. p. 503-532. 
47. Hohfeld, J., D.M. Cyr, and C. Patterson, From the cradle to the grave: 
molecular chaperones that may choose between folding and degradation. 
Embo Reports, 2001. 2(10): p. 885-890. 
48. Cohen, E.A., et al., SPECIFIC-INHIBITION OF HERPESVIRUS 
RIBONUCLEOTIDE REDUCTASE BY A NONAPEPTIDE DERIVED 
 32 
FROM THE CARBOXY TERMINUS OF SUBUNIT-2. Nature, 1986. 
321(6068): p. 441-443. 
49. Dutia, B.M., et al., SPECIFIC-INHIBITION OF HERPESVIRUS 
RIBONUCLEOTIDE REDUCTASE BY SYNTHETIC PEPTIDES. Nature, 
1986. 321(6068): p. 439-441. 
50. Tilley, J.W., et al., Identification of a Small Molecule Inhibitor of the IL-2/IL-
2RŒ± Receptor Interaction Which Binds to IL-2. Journal of the American 
Chemical Society, 1997. 119(32): p. 7589-7590. 
51. Raimundo, B.C., et al., Integrating Fragment Assembly and Biophysical 
Methods in the Chemical Advancement of Small-Molecule Antagonists of 
IL-2:‚Äâ An Approach for Inhibiting Protein‚àíProtein Interactions‚Ä†. 
Journal of Medicinal Chemistry, 2004. 47(12): p. 3111-3130. 
52. Thanos, C.D., W.L. DeLano, and J.A. Wells, Hot-spot mimicry of a 
cytokine receptor by a small molecule. Proceedings of the National 
Academy of Sciences, 2006. 103(42): p. 15422-15427. 
53. Fry, D.C., et al., NMR structure of a complex between MDM2 and a small 
molecule inhibitor. Journal of Biomolecular NMR, 2004. 30(2): p. 163-173. 
54. Vassilev, L.T., et al., In vivo activation of the p53 pathway by small-
molecule antagonists of MDM2. Science, 2004. 303(5659): p. 844-848. 
55. Ding, K., et al., Structure-Based Design of Potent Non-Peptide MDM2 
Inhibitors. Journal of the American Chemical Society, 2005. 127(29): p. 
10130-10131. 
56. Shangary, S., et al., Temporal activation of p53 by a specific MDM2 
inhibitor is selectively toxic to tumors and leads to complete tumor growth 
inhibition. Proceedings of the National Academy of Sciences, 2008. 
105(10): p. 3933-3938. 
57. Wang, G.P., et al., Structure-based design of potent small-molecule 
inhibitors of anti-apoptotic Bcl-2 proteins. Journal of Medicinal Chemistry, 
2006. 49(21): p. 6139-6142. 
58. Ding, K., et al., Structure-based design of spiro-oxindoles as potent, 
specific small-molecule inhibitors of the MDM2-p53 interaction. Journal of 
Medicinal Chemistry, 2006. 49(12): p. 3432-3435. 
59. Bruncko, M., et al., Studies leading to potent, dual inhibitors of bcl-2 and 
Bcl-xL. Journal of Medicinal Chemistry, 2007. 50(4): p. 641-662. 
60. Oltersdorf, T., et al., An inhibitor of Bcl-2 family proteins induces 
regression of solid tumours. Nature, 2005. 435(7042): p. 677-681. 
61. Murray, C.W. and D.C. Rees, The rise of fragment-based drug discovery. 
Nat Chem, 2009. 1(3): p. 187-192. 
62. Gorczynski, M.J., et al., Allosteric inhibition of the protein-protein 
interaction between the leukemia-associated proteins Runx1 and CBF 
beta. Chemistry & Biology, 2007. 14(10): p. 1186-1197. 
63. Grembecka, J., et al., Menin-MLL inhibitors reverse oncogenic activity of 
MLL fusion proteins in leukemia. Nature Chemical Biology, 2012. 8(3): p. 
277-284. 
 33 
64. Frankel, A.D. and J.A.T. Young, HIV-1: Fifteen Proteins and an RNA. 
Annual Review of Biochemistry, 1998. 67(1): p. 1-25. 
65. Weber, I.T., COMPARISON OF THE CRYSTAL-STRUCTURES AND 
INTERSUBUNIT INTERACTIONS OF HUMAN IMMUNODEFICIENCY 
AND ROUS-SARCOMA VIRUS PROTEASES. Journal of Biological 
Chemistry, 1990. 265(18): p. 10492-10496. 
66. Zhang, Z.Y., et al., DISSOCIATIVE INHIBITION OF DIMERIC ENZYMES 
- KINETIC CHARACTERIZATION OF THE INHIBITION OF HIV-1 
PROTEASE BY ITS COOH-TERMINAL TETRAPEPTIDE. Journal of 
Biological Chemistry, 1991. 266(24): p. 15591-15594. 
67. Ding, J., et al., Buried surface analysis of HIV-1 reverse transcriptase 
p66/p51 heterodimer and its interaction with dsDNA template/primer. 
Journal of Molecular Recognition, 1994. 7(2): p. 157-161. 
68. Divita, G., T. Restle, and R.S. Goody, CHARACTERIZATION OF THE 
DIMERIZATION PROCESS OF HIV-1 REVERSE-TRANSCRIPTASE 
HETERODIMER USING INTRINSIC PROTEIN FLUORESCENCE. Febs 
Letters, 1993. 324(2): p. 153-158. 
69. Fan, X., G.R. Flentke, and D.H. Rich, Inhibition of HIV-1 Protease by a 
Subunit of Didemnaketal A. Journal of the American Chemical Society, 
1998. 120(34): p. 8893-8894. 
70. Quere, L., T. Wenger, and H.J. Schramm, Triterpenes as Potential 
Dimerization Inhibitors of HIV-1 Protease. Biochemical and Biophysical 
Research Communications, 1996. 227(2): p. 484-488. 
71. Balzarini, J., et al., 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-
amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside 
analogues: highlyselective inhibitors of human immunodeficiency virus 
type 1 that are targeted at the viral reverse transcriptase. Proceedings of 
the National Academy of Sciences, 1992. 89(10): p. 4392-4396. 
72. Bonache, M.a.-C., et al., Improving the Antiviral Efficacy and Selectivity of 
HIV-1 Reverse Transcriptase Inhibitor TSAO-T by the Introduction of 
Functional Groups at the N-3 Position. Journal of Medicinal Chemistry, 
2005. 48(21): p. 6653-6660. 
73. Graham, T.A., et al., Crystal Structure of a β-Catenin/Tcf Complex. Cell, 
2000. 103(6): p. 885-896. 
74. Lepourcelet, M., et al., Small-molecule antagonists of the oncogenic Tcf/β-
catenin protein complex. Cancer Cell, 2004. 5(1): p. 91-102. 
75. Tian, W., et al., Structure-Based Discovery of a Novel Inhibitor Targeting 
the β-Catenin/Tcf4 Interaction. Biochemistry, 2012. 51(2): p. 724-731. 
76. Amin, A.R. and S.B. Abramson, The role of nitric oxide in articular 
cartilage breakdown in osteoarthritis. Current Opinion in Rheumatology, 
1998. 10(3): p. 263-268. 
77. Nathan, C. and Q.W. Xie, NITRIC-OXIDE SYNTHASES - ROLES, TOLLS, 
AND CONTROLS. Cell, 1994. 78(6): p. 915-918. 
 34 
78. McMillan, K., et al., Allosteric inhibitors of inducible nitric oxide synthase 
dimerization discovered via combinatorial chemistry. Proceedings of the 
National Academy of Sciences, 2000. 97(4): p. 1506-1511. 
79. Lee, G.M. and C.S. Craik, Trapping Moving Targets with Small Molecules. 
Science, 2009. 324(5924): p. 213-215. 
80. Fieber, W., et al., Structure, function, and dynamics of the dimerization 
and DNA-binding domain of oncogenic transcription factor v-Myc. Journal 
of Molecular Biology, 2001. 307(5): p. 1395-1410. 
81. Kiessling, A., et al., Selective inhibition of c-Myc/Max dimerization and 
DNA binding by small molecules. Chemistry & Biology, 2006. 13(7): p. 
745-751. 
82. Silvian, L.F., et al., Small Molecule Inhibition of the TNF Family Cytokine 
CD40 Ligand through a Subunit Fracture Mechanism. Acs Chemical 
Biology, 2011. 6(6): p. 636-647. 
83. He, M.M., et al., Small-molecule inhibition of TNF-alpha. Science, 2005. 
310(5750): p. 1022-1025. 
84. Magliery, T.J., et al., Detecting protein-protein interactions with a green 
fluorescent protein fragment reassembly trap: Scope and mechanism. 
Journal of the American Chemical Society, 2005. 127(1): p. 146-157. 
85. Liu, B., et al., Label Transfer Chemistry for the Characterization of 
Protein‚àíProtein Interactions. Journal of the American Chemical Society, 
2007. 129(41): p. 12348-12349. 
86. Heeres, J.T., et al., Identifying Modulators of Protein‚àíProtein Interactions 
Using Photonic Crystal Biosensors. Journal of the American Chemical 
Society, 2009. 131(51): p. 18202-18203. 
87. Porter, J.R., et al., A General and Rapid Cell-Free Approach for the 
Interrogation of Protein‚àíProtein, Protein‚àíDNA, and Protein‚àíRNA 
Interactions and their Antagonists Utilizing Split-Protein Reporters. Journal 
of the American Chemical Society, 2008. 130(20): p. 6488-6497. 
88. Moerke, N.J., et al., Small-molecule inhibition of the interaction between 
the translation initiation factors eIF4E and eIF4G. Cell, 2007. 128(2): p. 
257-267. 
89. Roman, D.L., et al., Identification of Small-Molecule Inhibitors of RGS4 
Using a High-Throughput Flow Cytometry Protein Interaction Assay. 
Molecular Pharmacology, 2007. 71(1): p. 169-175. 
90. Potashman, M.H. and M.E. Duggan, Covalent Modifiers: An Orthogonal 
Approach to Drug Design. Journal of Medicinal Chemistry, 2009. 52(5): p. 
1231-1246. 
91. Reinke, A.A. and J.E. Gestwicki, Insight into Amyloid Structure Using 
Chemical Probes. Chemical Biology & Drug Design, 2011. 77(6): p. 399-
411. 
92. Eisenberg, D. and M. Jucker, The amyloid state of proteins in human 
diseases. Cell, 2012. 148(6): p. 1188-203. 
 35 
93. Findeis, M.A., Approaches to discovery and characterization of inhibitors 
of amyloid beta-peptide polymerization. Biochimica Et Biophysica Acta-
Molecular Basis of Disease, 2000. 1502(1): p. 76-84. 
94. Lee, V.M.Y., Amyloid binding ligands as Alzheimer's disease therapies. 
Neurobiology of Aging, 2002. 23(6): p. 1039-1042. 
95. Bose, M., et al., 'Nature-inspired' drug-protein complexes as inhibitors of A 
beta aggregation. Biochemical Society Transactions, 2005. 33: p. 543-
547. 
96. Roberts, B.E., et al., A synergistic small-molecule combination directly 
eradicates diverse prion strain structures. Nat Chem Biol, 2009. 5(12): p. 
936-946. 
97. Schmid, E.M. and H.T. McMahon, Integrating molecular and network 
biology to decode endocytosis. Nature, 2007. 448(7156): p. 883-888. 
98. von Kleist, L., et al., Role of the Clathrin Terminal Domain in Regulating 
Coated Pit Dynamics Revealed by Small Molecule Inhibition. Cell, 2011. 
146(3): p. 471-484. 
99. Lee, L.W. and A.K. Mapp, Transcriptional Switches: Chemical Approaches 
to Gene Regulation. Journal of Biological Chemistry, 2010. 285(15): p. 
11033-11038. 
100. Buhrlage, S.J., et al., Amphipathic Small Molecules Mimic the Binding 
Mode and Function of Endogenous Transcription Factors. Acs Chemical 
Biology, 2009. 4(5): p. 335-344. 
101. Casey, R.J., et al., Expanding the repertoire of small molecule 
transcriptional activation domains. Bioorganic &amp; Medicinal Chemistry, 
2009. 17(3): p. 1034-1043. 
102. Boriack-Sjodin, P.A., et al., The structural basis of the activation of Ras by 
Sos. Nature, 1998. 394(6691): p. 337-343. 
103. Sondermann, H., et al., Structural Analysis of Autoinhibition in the Ras 
Activator Son of Sevenless. Cell, 2004. 119(3): p. 393-405. 
104. Patgiri, A., et al., An orthosteric inhibitor of the Ras-Sos interaction. Nat 
Chem Biol, 2011. 7(9): p. 585-587. 
105. Maurer, T., et al., Small-molecule ligands bind to a distinct pocket in Ras 
and inhibit SOS-mediated nucleotide exchange activity. Proceedings of 
the National Academy of Sciences, 2012. 109(14): p. 5299-5304. 
106. Kiessling, L.L., J.E. Gestwicki, and L.E. Strong, Synthetic Multivalent 
Ligands as Probes of Signal Transduction. Angewandte Chemie 
International Edition, 2006. 45(15): p. 2348-2368. 
107. Evans, C.G., L. Chang, and J.E. Gestwicki, Heat Shock Protein 70 
(Hsp70) as an Emerging Drug Target. Journal of Medicinal Chemistry, 
2010. 53(12): p. 4585-4602. 
108. Patury, S., Y. Miyata, and J.E. Gestwicki, Pharmacological Targeting of 
the Hsp70 Chaperone. Current Topics in Medicinal Chemistry, 2009. 
9(15): p. 1337-1351. 
 36 
109. Brodsky, J.L. and G. Chiosis, Hsp70 molecular chaperones: Emerging 
roles in human disease and identification of small molecule modulators. 
Current Topics in Medicinal Chemistry, 2006. 6(11): p. 1215-1225. 
110. Brandt, G.E.L. and B.S.J. Blagg, Alternate Strategies of Hsp90 Modulation 
for the Treatment of Cancer and Other Diseases. Current Topics in 
Medicinal Chemistry, 2009. 9(15): p. 1447-1461. 
111. Powers, M.V. and P. Workman, Inhibitors of the heat shock response: 
Biology and pharmacology. Febs Letters, 2007. 581(19): p. 3758-3769. 
112. Hartl, F.U. and M. Hayer-Hartl, Converging concepts of protein folding in 
vitro and in vivo. Nat Struct Mol Biol, 2009. 16(6): p. 574-581. 
113. Meimaridou, E., S.B. Gooljar, and J.P. Chapple, From hatching to 
dispatching: the multiple cellular roles of the Hsp70 molecular chaperone 
machinery. Journal of Molecular Endocrinology, 2009. 42(1-2): p. 1-9. 
114. Massey, A.J., ATPases as Drug Targets: Insights from Heat Shock 
Proteins 70 and 90. Journal of Medicinal Chemistry, 2010. 53(20): p. 
7280-7286. 
115. Miyata, Y., et al., Molecular chaperones and regulation of tau quality 
control: strategies for drug discovery in tauopathies. Future Medicinal 
Chemistry, 2011. 3(12): p. 1523-1537. 
116. Kampinga, H.H. and E.A. Craig, The HSP70 chaperone machinery: J 
proteins as drivers of functional specificity. Nature Reviews Molecular Cell 
Biology, 2010. 11(8): p. 579-592. 
117. Ahmad, A., et al., Heat shock protein 70¬†kDa chaperone/DnaJ 
cochaperone complex employs an unusual dynamic interface. 
Proceedings of the National Academy of Sciences, 2011. 108(47): p. 
18966-18971. 
118. Jiang, J., et al., Structural Basis of J Cochaperone Binding and Regulation 
of Hsp70. Molecular cell, 2007. 28(3): p. 422-433. 
119. Harrison, C.J., et al., Crystal Structure of the Nucleotide Exchange Factor 
GrpE Bound to the ATPase Domain of the Molecular Chaperone DnaK. 
Science, 1997. 276(5311): p. 431-435. 
120. Schmid, A.B., et al., The architecture of functional modules in the Hsp90 
co-chaperone Sti1/Hop. EMBO J, 2012. 31(6): p. 1506-1517. 
121. Scheufler, C., et al., Structure of TPR Domain-Peptide Complexes: Critical 
Elements in the Assembly of the Hsp70-Hsp90 Multichaperone Machine. 
Cell, 2000. 101(2): p. 199-210. 
122. Wisen, S., et al., Binding of a Small Molecule at a Protein-Protein Interface 
Regulates the Chaperone Activity of Hsp70-Hsp40. Acs Chemical Biology, 
2010. 5(6): p. 611-622. 
123. Chang, L., et al., Chemical Screens against a Reconstituted Multiprotein 
Complex: Myricetin Blocks DnaJ Regulation of DnaK through an Allosteric 
Mechanism. Chemistry &amp; Biology, 2011. 18(2): p. 210-221. 
 37 
124. Bhattacharya, A., et al., Allostery in Hsp70 Chaperones Is Transduced by 
Subdomain Rotations. Journal of Molecular Biology, 2009. 388(3): p. 475-
490. 
125. Chang, L., et al., High-throughput screen for small molecules that 
modulate the ATPase activity of the molecular chaperone DnaK. Analytical 
Biochemistry, 2008. 372(2): p. 167-176. 
126. Miyata, Y., et al., High-Throughput Screen for Escherichia coli Heat Shock 
Protein 70 (Hsp70/DnaK): ATPase Assay in Low Volume by Exploiting 
Energy Transfer. Journal of Biomolecular Screening, 2010. 15(10): p. 
1211-1219. 
127. Kettern, N., et al., Chaperone-assisted degradation: multiple paths to 
destruction. Biological Chemistry, 2011. 391(5): p. 481-489. 
128. Allan, R.K. and T. Ratajczak, Versatile TPR domains accommodate 
different modes of target protein recognition and function. Cell Stress & 
Chaperones, 2011. 16(4): p. 353-367. 
129. Leu, J.I.J., et al., A Small Molecule Inhibitor of Inducible Heat Shock 
Protein 70. Molecular cell, 2009. 36(1): p. 15-27. 
130. Li, J., J. Soroka, and J. Buchner, The Hsp90 chaperone machinery: 
Conformational dynamics and regulation by co-chaperones. Biochimica et 
Biophysica Acta (BBA) - Molecular Cell Research, 2012. 1823(3): p. 624-
635. 
131. Kamal, A., M.F. Boehm, and F.J. Burrows, Therapeutic and diagnostic 
implications of Hsp90 activation. Trends in molecular medicine, 2004. 
10(6): p. 283-290. 
132. Whitesell, L. and S.L. Lindquist, HSP90 and the chaperoning of cancer. 
Nat Rev Cancer, 2005. 5(10): p. 761-772. 
133. Porter, J.R., C.C. Fritz, and K.M. Depew, Discovery and development of 
Hsp90 inhibitors: a promising pathway for cancer therapy. Current Opinion 
in Chemical Biology, 2010. 14(3): p. 412-420. 
134. Bagatell, R., et al., Induction of a Heat Shock Factor 1-dependent Stress 
Response Alters the Cytotoxic Activity of Hsp90-binding Agents. Clinical 
Cancer Research, 2000. 6(8): p. 3312-3318. 
135. Donnelly, A. and B.S.J. Blagg, Novobiocin and Additional Inhibitors of the 
Hsp90 C-Terminal Nucleotide-binding Pocket. Current Medicinal 
Chemistry, 2008. 15(26): p. 2702-2717. 
136. Sreeramulu, S., et al., The Human Cdc37.Hsp90 Complex Studied by 
Heteronuclear NMR Spectroscopy. Journal of Biological Chemistry, 2009. 
284(6): p. 3885-3896. 
137. Meyer, P., et al., Structural basis for recruitment of the ATPase activator 
Aha1 to the Hsp90 chaperone machinery. EMBO J, 2004. 23(3): p. 511-
519. 
138. Siligardi, G., et al., Co-chaperone Regulation of Conformational Switching 
in the Hsp90 ATPase Cycle. Journal of Biological Chemistry, 2004. 
279(50): p. 51989-51998. 
 38 
139. Zhang, T., et al., Characterization of Celastrol to Inhibit Hsp90 and Cdc37 
Interaction. Journal of Biological Chemistry, 2009. 284(51): p. 35381-
35389. 
140. Sreeramulu, S., et al., Molecular Mechanism of Inhibition of the Human 
Protein Complex Hsp90–Cdc37, a Kinome Chaperone–Cochaperone, by 
Triterpene Celastrol. Angewandte Chemie International Edition, 2009. 
48(32): p. 5853-5855. 
141. Ardi, V.C., et al., Macrocycles That Inhibit the Binding between Heat 
Shock Protein 90 and TPR-Containing Proteins. Acs Chemical Biology, 
2011. 6(12): p. 1357-1366. 
142. Yi, F. and L. Regan, A Novel Class of Small Molecule Inhibitors of Hsp90. 
Acs Chemical Biology, 2008. 3(10): p. 645-654. 
143. Gandhi, P.S., et al., Structural identification of the pathway of long-range 
communication in an allosteric enzyme. Proceedings of the National 
Academy of Sciences, 2008. 105(6): p. 1832-1837. 
144. Motlagh, H.N. and V.J. Hilser, Agonism/antagonism switching in allosteric 
ensembles. Proceedings of the National Academy of Sciences, 2012. 
109(11): p. 4134-4139. 
145. Chari, A. and U. Fischer, Cellular strategies for the assembly of molecular 
machines. Trends in Biochemical Sciences, 2010. 35(12): p. 676-683. 
146. Peterson-Kaufman, K.J., et al., Nucleating the Assembly of 
Macromolecular Complexes. ChemBioChem, 2010. 11(14): p. 1955-1962. 
147. Good, M.C., J.G. Zalatan, and W.A. Lim, Scaffold Proteins: Hubs for 
Controlling the Flow of Cellular Information. Science, 2011. 332(6030): p. 
680-686. 
148. Cardinale, D., et al., Homodimeric Enzymes as Drug Targets. Current 
Medicinal Chemistry, 2010. 17(9): p. 826-846. 
149. Panda, K., et al., Distinct Dimer Interaction and Regulation in Nitric-oxide 
Synthase Types I, II, and III. Journal of Biological Chemistry, 2002. 
277(34): p. 31020-31030. 
150. Knapp, S., et al., Thermodynamics of the high-affinity interaction of TCF4 
with β-catenin. Journal of Molecular Biology, 2001. 306(5): p. 1179-1189. 
151. Rickert, M., et al., The Structure of Interleukin-2 Complexed with Its Alpha 
Receptor. Science, 2005. 308(5727): p. 1477-1480. 
152. Braisted, A.C., et al., Discovery of a Potent Small Molecule IL-2 Inhibitor 
through Fragment Assembly. Journal of the American Chemical Society, 
2003. 125(13): p. 3714-3715. 
153. Raimundo, B.C., et al., Integrating Fragment Assembly and Biophysical 
Methods in the Chemical Advancement of Small-Molecule Antagonists of 
IL-2: An Approach for Inhibiting Protein-Protein Interactions. Journal of 
Medicinal Chemistry, 2004. 47(12): p. 3111-3130. 
154. Yu, G.W., et al., The central region of HDM2 provides a second binding 
site for p53. Proceedings of the National Academy of Sciences of the 
United States of America, 2006. 103(5): p. 1227-1232. 
 39 
155. Kussie, P.H., et al., Structure of the MDM2 oncoprotein bound to the p53 
tumor suppressor transactivation domain. Science, 1996. 274(5289): p. 
948-953. 
156. Grasberger, B.L., et al., Discovery and Cocrystal Structure of 
Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells. 
Journal of Medicinal Chemistry, 2005. 48(4): p. 909-912. 
157. Sattler, M., et al., Structure of Bcl-x(L)-Bak peptide complex: Recognition 
between regulators of apoptosis. Science, 1997. 275(5302): p. 983-986. 
158. Tang, G., et al., Pyrogallol-Based Molecules as Potent Inhibitors of the 
Antiapoptotic Bcl-2 Proteins. Journal of Medicinal Chemistry, 2007. 50(8): 
p. 1723-1726. 
159. Abbate, E.A., J.M. Berger, and M.R. Botchan, The X-ray structure of the 
papillomavirus helicase in complex with its molecular matchmaker E2. 
Genes & Development, 2004. 18(16): p. 1981-1996. 
160. Wang, Y., et al., Crystal Structure of the E2 Transactivation Domain of 
Human Papillomavirus Type 11 Bound to a Protein Interaction Inhibitor. 
Journal of Biological Chemistry, 2004. 279(8): p. 6976-6985. 
161. Edeling, M.A., C. Smith, and D. Owen, Life of a clathrin coat: insights from 
clathrin and AP structures. Nat Rev Mol Cell Biol, 2006. 7(1): p. 32-44. 
162. Miele, A.E., et al., Two distinct interaction motifs in amphiphysin bind two 
independent sites on the clathrin terminal domain [beta]-propeller. Nat 
Struct Mol Biol, 2004. 11(3): p. 242-248. 
163. Siligardi, G., et al., Regulation of Hsp90 ATPase Activity by the Co-
chaperone Cdc37p/p50 cdc37. Journal of Biological Chemistry, 2002. 
277(23): p. 20151-20159. 
164. Mosyak, L., et al., The bacterial cell-division protein ZipA and its 
interaction with an FtsZ fragment revealed by X-ray crystallography. 
EMBO J, 2000. 19(13): p. 3179-3191. 
165. Rush, T.S., et al., A Shape-Based 3-D Scaffold Hopping Method and Its 
Application to a Bacterial Protein-Protein Interaction. Journal of Medicinal 








Characterization of the binding of the E3 ubiquitin ligase CHIP to the 
molecular chaperones Hsp70 and Hsp90 
 
2.1. Abstract 
One of the major cellular roles for the molecular chaperones, heat shock protein 
70 (Hsp70) and heat shock protein 90 (Hsp90) is to triage misfolded proteins. 
Both of these chaperones use protein-protein interactions (PPIs) with the E3 
ubiquitin ligase CHIP (C-terminus of Hsc70 interacting protein) to facilitate the 
degradation of their protein substrates. The complex between CHIP and Hsp70 
or Hsp90 facilitates proteasomal degradation through the attachment of poly-
ubiquitin chains to the chaperone-bound substrate. Qualitative studies have 
shown that CHIP binds to the C-termini of either Hsp70 or Hsp90 through its 
tetratricopeptide (TPR) domains, however, less is known about the affinity of the 
CHIP-Hsp70 and CHIP-Hsp90 interactions and whether regions outside the TPR 
domain contribute to binding. Towards these questions, we measured the affinity 
of CHIP for Hsp70 and Hsp90 using two independent assays and mapped the 
key interacting domains using truncation mutants. These studies showed that 
~80% of the binding free energy is associated with CHIP interacting with the C-
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terminal “lid” subdomain of Hsp70. However, additional contacts between the 
substrate-binding domain (SBD) of Hsp70 and the coiled-coil region of CHIP also 
make a significant contribution, resulting in a 2-fold tighter affinity of CHIP for 
Hsp70 compared to Hsp90. We also found that the TPR domain of CHIP is 
essential for in vitro ubiquitin transfer to Hsp70. Together, these studies suggest 
that multivalent interactions facilitate protein turnover, possibly by fine-tuning the 
relative position of chaperone, substrate and CHIP in the complex.  
 
2.1.1. Hsp70 and Hsp90 promote the degradation of misfolded proteins 
The molecular chaperones Hsp70 and Hsp90 maintain protein homeostasis by 
assisting in the folding, trafficking and turnover of proteins [1, 2]. Both of these 
chaperones are ATP hydrolyzing enzymes that bind to their “clients” in a 
nucleotide-dependent manner [3, 4]. When Hsp70, Hps90 and their associated 
co-chaperones encounter a denatured protein, they are thought to first attempt to 
rescue it via the folding pathway [5, 6]. However, when these attempts fail, Hsp70 
and Hsp90 have also been linked to the degradation of clients via the ubiquitin-
proteasome system (UPS) [7-9]. Together, these alternating pro-folding and pro-
degradation functions help coordinate protein quality control decisions and 




Proteins destined for degradation by the UPS are often labeled with a 
polyubiquitin chain via the activity of activating (E1), conjugating (E2) and ligase 
(E3) enzymes [13], which enhances the affinity of the protein for the 26S 
proteasome [14]. There is considerable evidence that Hsp70 and Hsp90 promote 
degradation of certain substrates, such as glucocorticoid receptors (GR) [15], 
cystic fibrosis transmembrane conductance regulator (CFTR) [16], and the 
microtubule associated protein tau (MAPT) [17], by directly recruiting ubiquitin E3 
ligases [18, 19]. For example, the E3 ligase CHIP appears to be an especially 
important partner in this chaperone-mediated polyubiquitination [20-22]. For 
some chaperone clients, such as the GR, CHIP even appears to be the major 
dedicated E3 ligase responsible for turnover, whereas other substrates, such as 
neuronal nitric oxide synthase (nNOS), can be degraded via the chaperone-
mediated action of multiple E3 ligases [23]. 
 
2.1.2. CHIP binds to chaperones through its TPR domain  
CHIP is a 35 kDa protein that contains a tetratricopeptide repeat (TPR) domain. 
The TPR domain is a common protein-protein interaction motif characterized by a 
tandem arrangement of three 34 amino acid motifs that forms an anti-parallel α-
helical hairpin [24, 25]. TPR domains are found in several Hsp70- and Hsp90-
associated co-chaperones and both chaperones are thought to interact with TPR 
domains via the conserved ʻEEVDʼ motifs located in their C-termini [20, 26]. Co-
crystal structures of the TPR domain of the co-chaperone, HOP (Hsp70-Hsp90 
  43 
organizing protein), bound to the EEVD motif of Hsp70 suggest that the extended 
polypeptide resides in a charged groove, with key electrostatic interactions 
between the C-terminal aspartate acting as a carboxylate clamp [27]. Outside of 
the EEVD motif, Hsp70 and Hsp90 have very little sequence or structural 
similarity, but they converge on binding to CHIP and other TPR domain co-
chaperones through this shared peptide motif. These protein-protein interactions 
(PPIs) are thought to enable turnover of clients by recruiting ubiquitin transfer 
activity to the vicinity of chaperone-associated, misfolded substrates [28].   
 
  44 
Despite the importance of the CHIP-Hsp70 and CHIP-Hsp90 complexes in 
protein homeostasis, surprisingly little is known about the affinities of these 
interactions. Moreover, it isnʼt clear whether contact surfaces outside the EEVD-
TPR interaction also contribute to the binding free energy. Most of what is known 
comes from qualitative pull-down experiments, especially glutathione-S-
transferase (GST) fusion protein assays [20, 28, 29]. Based on these studies, the 
TPR domain and an adjacent charged region of CHIP appear to be important for 
its interaction with Hsp70. Likewise similar approaches have been used to 
suggest that the carboxy terminal domain (CTD) of Hsp70, including the EEVD 
motif, seems to be required [28]. However, quantitative studies performed on the 
Hop-Hsp70 complex suggest that binding in that system involves additional 
contacts outside the TPR-EEVD [30]. Further, a recent cryo-EM structure of the 
Hsp70-Hop-Hsp90 complex also supports the idea that the interaction surface 
may be more extensive [31]. 
 
Here, we quantified the free energy contributions of the major domains in the 
CHIP-Hsp70 and CHIP-Hsp90 complexes. We report that CHIP binding to the 
CTD of Hsp70 contributes a majority (~80%) of the interaction energy, while 
Hsp70 additionally interacts with CHIP via a second contact in its substrate-
binding domain (SBD). This extra contact likely accounts for the 2-fold higher 
affinity for the CHIP-Hsp70 interaction over CHIP-Hsp90. These findings help 
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2.2.1. Design of CHIP and Hsp70 truncations  
Pioneering analyses on the Hsp70-CHIP complex were performed by Ballinger et 
al [20], in which they generated a series of truncation mutants of both CHIP and 
Hsp70 and then qualitatively evaluated the impact of individual domains using 
pulldowns. To extend that work, we were interested in quantifying the binding 
affinities of the various domains in an in vitro system. Accordingly, we designed a 
set of deletion constructs including, a CHIP TPR domain deletion (CHIPΔTPR) 
and two C-terminal truncations 1-142 and 1-197 (CHIP 1-142 and CHIP 1-197, 
respectively) (Figure 2.1). We also deleted the first 25 amino acids of CHIP, 
which have been shown to be important in auto-ubiquitination (CHIP Δ25). 
 
Hsp70 deletions included removal of the EEVD motif (Hsp70-ΔEEVD), the C-
terminal “lid” sub-domain (CTD) (Hsp70 1-555) and the entire substrate-binding 
domain (SBD) of Hsp70 to retain only the nucleotide-binding domain (NBD) 
(Hsp70-NBD). We also purified the prokaryotic Hsp70, DnaK, which naturally 
lacks the EEVD motif. Finally, we expressed and purified full length human 
Hsp90α (herein referred to as Hsp90) to permit comparisons between the two 
chaperones. Together, this collection of full length and truncated partners was 
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expected to provide insight into the contributions of various domains to the affinity 
of the CHIP-Hsp70 and CHIP-Hsp90 complexes. 
 
2.2.2. Full binding of CHIP to Hsp70 and Hsp90 requires an intact TPR 
domain, but other regions also contribute 
In order to measure the binding affinities of CHIP and Hsp70 or Hsp90, we first 
developed a homogeneous, solution phase, fluorescence quenching assay. 
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Briefly, Hsp70 and Hsp90 were labeled on exposed amines with the fluorescent 
donor AlexaFluor488 (AF488), which has an emission wavelength of 525 nm, 
and CHIP was similarly labeled with Black Hole Quencher10 (BHQ10), a strong 
fluorescence acceptor that absorbs at 507 nm. This simple system allows 
sensitive measurement of protein-protein interaction affinities, which are 
estimated from the quench in AF488 fluorescence [32, 33]. At a 50 nM 
concentration for both labeled Hsp70 and Hsp90, increasing concentrations of 
labeled CHIP produced a dose-dependent quench of the AF488 signal, giving 
apparent Kd values of ~ 60 nM and 80 nM for Hsp70 and Hsp90, respectively 
(Figure 2.2A). Encouragingly, DnaK, which does not bind CHIP, had a much 
weaker affinity (Kd > 1400 nM; Figure 2.2A). Additionally, labeled CHIP is not 
interacting with chaperone proteins as a substrate, as the synthetic peptide 
substrate NRLLLTG does not compete for labeled protein interactions in this 
assay (Appendix 2.5.1), suggesting that the interactions are specific.  
 
Next, using unlabeled chaperone protein as a positive control, we tested the 
ability of either full-length CHIP or CHIP without its TPR domain (CHIP-ΔTPR) to 
compete for the interaction of labeled protein. Saturating concentrations of the 
unlabeled competitor should restore the AF488 signal back to baseline 
fluorescence. In this experiment, both labeled Hsp70 and Hsp90 were at 50 nM, 
while labeled CHIP was at 50 nM and 80 nM, respectively. Unlabeled CHIP 
competed with the labeled protein interaction (Figure 2.2B-C). Interestingly,  
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CHIP-ΔTPR retained some ability to compete for binding both Hsp70 and Hsp90 
(Figure 2.2B-C; Table 2.1), suggesting that regions besides the TPR domain of 
CHIP contribute to binding chaperone proteins.  
 
2.2.3. CHIP binds to Hsp90 
with weaker affinity than 
Hsp70  
To confirm and expand upon 
our results from the 
fluorescence quenching 
assay, we developed a 
secondary, label-free, surface 
plasmon resonance (SPR) 
platform to measure the affinities of Hsp70 and Hsp90 for CHIP. This was 
important because the difference between the Ki values for unlabeled protein 
competition (Table 2.1) and the Kd values from the quenching assay (Figure 
2.2A) suggests that the labeling in this assay affects the interaction, making 
interpretation difficult. Biotinylated Hsp70 was immobilized on a streptavidin 
Biacore chip (SA), at a density of ~1000 response units (RUs). Binding of 
recombinant CHIP was evaluated by injecting concentrations ranging from 0 to 
500 nM at a flow rate of 20 µL/min. Binding was measured by first subtracting the 
signal from a control lane in which DnaK was immobilized, but binding to this 
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control was not significant (ΔRUmax < 20). Binding affinities were then determined 
using analyses of equilibrium binding values (Figure 2.3A). For the binding of full 
length Hsp70 to CHIP, the apparent Kd was determined to be 190 ± 3.6 nM 
(Figure 2.3B). This observed affinity is 3-fold weaker than that predicted by the 
fluorescence quenching assay, suggesting that either the SA surface may 
partially interfere with binding or, as previously observed, affinities in the 
quenching assay are influenced by labeling. To confirm that the observed 
interaction was specific, we verified that free Hsp70 competed with CHIP for 
binding to the surface. This experiment provided a Ki of ~ 340 nM at either of two 
different concentrations of CHIP (100 nM and 250 nM), suggesting that the 
interaction is indeed specific (Figure 2.3C). We noted that the Ki value was larger 
than the observed Kd, perhaps because of contributions from multivalent binding 
at the SA-chip surface. 
 
CHIP has been shown to bind both Hsp90 and Hsp70, guiding triage decisions 
during protein quality control [28]. Traditionally, Hsp70 is more closely associated 
with CHIP-mediated degradation, while Hsp90 is considered a stabilizing 
chaperone [9]. However, other studies have shown that Hsp90, not Hsp70, is 
more closely linked to degradation of some substrates, such as VHL [34, 35]. To 
better understand this system, biotinylated Hsp90 (1950 RUs) was immobilized 
on an SA chip and then full length CHIP was injected at a flow rate of 20 µL/min. 
These studies showed that CHIP bound Hsp90 with a 2-fold weaker affinity (Kd = 
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380 ± 29 nM) than Hsp70 (Figure 2.3D). This conclusion was supported by the 
results of the quenching studies in which labeled Hsp90 bound labeled CHIP with 
an apparent Kd of 82 ± 7 nM, approximately 1.6-fold weaker than the Hsp70-
CHIP interaction (Figure 2.2A).  
 
2.2.4. Truncation mutants reveal domains critical for the Hsp70-CHIP 
interaction 
Because interactions between Hsp70 and CHIP seem to be more extensive than 
what has been previously reported, and Hsp70 binds CHIP with a 2-fold higher 
affinity over Hsp90, we next focused on the Hsp70-CHIP PPI to investigate what 
additional contacts outside of the EEVD-TPR interaction could account for these 
observations. Towards this goal, biotinylated Hsp70 truncations were immobilized 
on a SA-chip and binding of recombinant CHIP (and its truncations) was 
measured in a similar fashion as described above. Results from these 
experiments are summarized in Table 2.2. Consistent with the results from the 
fluorescence quenching assay, the TPR domain of CHIP is important for binding 
to Hsp70, as deletion of this domain results in a 3-fold loss in affinity (Kd = 601 ± 
54 nM). In addition, the coiled-coil region of CHIP also contributes, because CHIP 
1-142 had a 30% weaker affinity (Kd = 247 ± 36 nM) than full length. This is an 
interesting result because this domain is not conserved in other TPR proteins, 
suggesting that it may help contribute to specificity. The CHIP 1-197 and 
CHIPΔ25 proteins had affinities similar to full length CHIP, suggesting that the 
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deleted regions did not significantly contribute to Hsp70 binding (Table 2.2). 
Deletion of the EEVD region of Hsp70 resulted in a loss of only 2-fold in affinity 
(Kd = 430 ± 36 nM).  The Hsp70 1-555 construct was still able to weakly bind to 
CHIP (Kd = 835 ± 44 nM), suggesting that regions of the substrate-binding 
domain (SBD) outside the C-terminal lid also participate in binding CHIP. This 
interaction likely involves contacts with the TPR and coiled-coil regions of CHIP, 
because Hsp70 1-555 had no appreciable affinity for either CHIP 1-142 or CHIP-
ΔTPR (Kd > 5 µM). As expected [20], the NBD did not contribute to the 
interaction, as the Hsp70-NBD truncation did not have significant affinity (Kd > 5 
µM).  
 
As shown in Figure 2.2D and summarized in Table 2.1, the Hsp70 truncation 
results were consistent across platforms. The quenching assay also revealed 
that the Hsp70 EEVD motif is important for binding, as the Hsp70 ΔEEVD mutant 
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had a Ki value ~2.5-fold higher than full length (Ki =  82 ± 4.2 nM vs 36.60 ± 5.2 
nM). And interestingly, Hsp70 1-555 and Hsp70 NBD displayed progressively 
weaker binding to CHIP. Calculation of the free energy values from the affinities 
measured by SPR revealed that ~80% of the binding between CHIP and Hsp70 
can be attributed to interactions within the Hsp70 CTD (Appendix 2.5.5). This 
finding once again suggests that some binding energy for the full-length 
interaction is contained within areas of the SBD outside of the CTD. Taken 
together, these results show that binding of CHIP to the C-terminus of Hsp70, 
while certainly a contributor to the PPI, is not sufficient to describe the entire 
affinity. Additionally, they provide insight into the requirements for forming a 
complex between Hsp70 and CHIP. 
 
2.2.5. CHIP does not display nucleotide dependence in binding to Hsp70 
Since nucleotide binding and hydrolysis result in conformational changes in 
Hsp70 [36, 37], we wanted to measure the binding affinities for CHIP under 
different nucleotide states. Nucleotide dependence has already been shown for 
the TPR-domain co-chaperone, Hop, which binds Hsp70 in the ADP-bound 
conformation 2-fold better than Hsp70-ATP [38]. In contrast, our results showed 
that CHIP did not have a preference for Hsp70ʼs nucleotide state; similar affinities 
of ~ 200 to 240 nM were found for Hsp70 in the ATP, ADP and apo states by 
SPR (Figure 2.4A) and ~ 55 nM for Hsp70 in the presence of either ATP, ADP or 
AMP-PnP in the fluorescence quench assay (Figure 2.4B). 
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These findings suggest that CHIP does not have a preference for nucleotide 
states of Hsp70 and, therefore, it might not be expected to have any effect on 
steady state ATP turnover in the chaperone. To test CHIP in this setting, steady 
state ATPase assays on full length Hsp70 were performed, showing that CHIP 
neither increased nor decreased the rate of ATP hydrolysis (Figure 2.4C). In 
contrast, the well-known J domain co-chaperone, DJA2 (DnaJA2), was a potent 
stimulator of this activity (Figure 2.4C). These studies suggest that CHIP binding 
occurs independent of nucleotide state and that it does not allosterically impact 
Hsp70 enzymatic activity. 
 
2.2.6. TPR domain is required for the ubiquitination of Hsp70  
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CHIP ubiquitinates Hsp70 in cells and this activity is thought to promote turnover 
of both the chaperone and its bound substrates [39]. Based on our biochemical 
studies, we wanted to assess which domains are necessary for this enzymatic 
function of CHIP. Using in vitro ubiquitination assays, CHIP and Hsp70 were 
incubated with a mixture of components required for the reconstitution of the 
ubiquitin cycle [14]: ubiquitin (Ub), E1 and E2 enzymes and ATP. Conjugation of 
ubiquitin to Hsp70 was then measured using Western blot analysis (Figure 2.5). 
Using a series of CHIP truncations, we found that both the ubiquitination domain 
by itself (Ubox) and CHIP ΔTPR lacked activity. Interestingly, deletion of just the 
first TPR motif in the CHIP sequence (Δ-TPR-1) also abolished activity. Thus, 
these studies strongly support a key, functional role for the TPR domains of CHIP 
in ubiquitination of Hsp70. 
  
2.3. Discussion 
2.3.1. The TPR domain in CHIP and the EEVD motif in Hsp70/Hsp90 play 
important roles in binding but other regions also contribute  
CHIP cooperates with the molecular chaperones Hsp70 and Hsp90 to play a 
central role in protein quality control [40, 41]. Here, we sought to measure the 
affinities of CHIP for Hsp70/90 and, further, determine which domains contribute 
to binding. Using SPR and fluorescence proximity assays, we found that the TPR 
domain in CHIP is important for binding to both Hsp70 and Hsp90, with the 
coiled-coil region also playing a role in binding Hsp70. On the other side, the 
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EEVD motif of both chaperones has historically been found to be important for 
binding [20, 26]. However, our data suggests that this region was not the only 
one involved in the interaction as the Hsp70 ΔEEVD truncation had only a 2-fold 
weaker affinity for CHIP. Further, the Hsp70 1-555 truncation retained weak 
binding affinity, suggesting that regions in the CTD and SBD also interact with 
CHIP. This result has some interesting parallels with studies on the Hop-Hsp70 
interaction [27], in which contacts outside the EEVD-TPR make important, 
secondary contributions. One result of this additional contact between Hsp70 and 
CHIP was an approximately 2-fold tighter affinity, compared to CHIP-Hsp90. 
 
Based on these 
measurements, we 
conclude that ~80% of 
the interaction energy 
from binding of Hsp70 to 
CHIP arises from 
interactions between 
CHIP and the C-terminal 
“lid” domain of Hsp70, 
while the remaining affinity comes from a poorly understood contact in the SBD. 
This secondary interaction is not due to non-specific binding of CHIP in the 
substrate binding cleft of Hsp70, because it was not influenced by saturating 
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levels of a model peptide substrate (see Appendix 2.5.1). Rather, we 
hypothesize that this additional contact might provide the Hsp70-CHIP complex 
with additional opportunities for fine-tuning the position of the substrate, CHIP 
and the E2 enzyme. There are many examples of Hsp70 being a critical partner 
for CHIP-mediated degradation of substrates [9], suggesting that, in some cases, 
the Hsp70-CHIP interaction may be especially suited for promoting turnover. 
However, in other cases, Hsp90 has clearly been shown to play a dominant role 
in chaperone-mediated turnover [35]. Our results suggest that the HSP90-CHIP 
interaction is only 2-fold weaker than the Hsp70-CHIP contact, supporting the 
idea that either chaperone can facilitate substrate turnover through the UPS. The 
ultimate choice of which chaperone partner becomes involved may be dictated by 
structural topology of the individual substrates, although more studies are 
certainly required to address this hypothesis. 
 
2.3.2. Nucleotide state does not influence CHIP binding to Hsp70  
Another TPR-domain containing co-chaperone, Hop, has been shown to 
preferentially bind Hsp70 in an ADP bound state [38]. Unexpectedly, the affinity 
of the CHIP-Hsp70 interaction was nucleotide independent and, further, it had no 
significant impact on ATP turnover by Hsp70. Thus, we propose that the Hop-
Hsp70 and CHIP-Hsp70 contact surface may be different, allowing 
communication of the nucleotide-specific conformation between Hop and Hsp70, 
  58 
but not CHIP and Hsp70. More work is required to understand this difference and 
learn its potential functional significance in protein quality control. 
 
2.4. Materials and methods 
2.4.1. Protein purification 
All Hsp70 proteins were derived from the human Hsp72 (HSP1A1). The Hsp90 
used in these studies was human Hsp90a-1. All Hsp70 truncations were cloned 
into the pMCSG7 plasmid (Midwest Center for Structural Genomics, Bethesda, 
MD) by ligation independent cloning and transformed into Rosetta (DE3) cells for 
expression. To express Hsp70 truncations, 25 mL of overnight (37 °C) LB culture 
of Rosetta (DE3) culture was poured into 1 L of Terrific Broth. After 3 hours 
incubation at 37 °C, the culture was cooled down to 28 °C for 2 hours before 
overnight induction of expression with 200 µM IPTG overnight, and the cell pellet 
was stored at -80 °C until use. The wt and Hsp70 truncations were purified using 
same procedures as described except the addition of the EDTA-free protease 
inhibitor cocktail (Roche) (1/4 tablet for each sample) in the lysis buffer and the 
omitting of final Ni-NTA resin clean-up step for Hsp70 truncations.  All CHIP 
truncations were expressed in E. coli (BL21 DE3 LysS) and purified on 
glutathione sepharose resin (GE Healthcare) [42, 43]. All GST tagged proteins 
were cleaved with Precission protease and purified prior to use. UbcH5c was 
purified as previously described [43]. 
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2.4.2. Surface plasmon resonance experiments 
A streptavidin chip (SA; GE Healthcare) was docked and equilibrated with HBS 
buffer (10 mM HEPES, 150 mM NaCl, pH 7.4 containing 0.005% Tween-20) 
overnight at 5 uL/min. All experiments were performed at 25 °C. Proteins were 
biotinylated using Sulpho-NHS-LC-Biotin (Invitrogen, catalog B-6353) following 
the protocol provided by Invitrogen (MP00143). Hsp70ʼs were immobilized in 
MES buffer (20mM MES, 150 mM NaCl, pH 5.5, 0.01% Tween-20). Average 
immobilization responses for the various Hsp70 truncations were approximately 
1200 RUs. After immobilization of all biotinylated proteins, the chip was 
equilibrated for at least 4 hours at 5 µL/min. Varying concentrations of CHIP and 
its truncations (10 nM to 2 µM) were prepared in HBS buffer and 40 µL were 
injected at 20 µL/min. For competition experiments, CHIP (100 nM) and 
unlabeled Hsp70 (50 nM – 10 µM) were combined in HBS immediately prior to 
injection. For both direct and competition binding, the binding surface was 
recovered with regeneration buffer (HBS buffer, 100 mM NaOH, 100 mM MgCl2), 
using a pulse injection of 20 µL until the baseline response was reached. 
Equilibrium data was fit using the RU values 5 seconds prior to the end of the 
association phase, followed by non-linear regression analysis using GraphPad 
Prism software. 
 
2.4.3. Analytical ultracentrifugation 
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Sedimentation velocity and equilibrium experiments were carried out in a 
Beckman XL-I ProteomeLab analytical ultracentrifuge with absorbance optics. 
Samples were prepared in 10 mM HEPES, 150 mM NaCl at pH 7.4. In the 
sedimentation velocity experiments, 400 µL of Hsp72 (10 µM) and CHIP (20 µM) 
were loaded into two-sector charcoal-filled epon centerpieces and spun at 48,000 
rpm at 20 °C. Data were analyzed using c(s) and c(M) models in SEDFIT. 
 
2.4.4. Gel filtration 
Purified protein was pre-incubated on ice in HEPES buffered saline (10 mM 
HEPES, 100 mM NaCl, pH 7.4) containing 1 mM ADP. Each sample was injected 
onto an analytical size exclusion column (Superdex 200, GE Healthcare) and run 
at 0.5 mL/min in HBS buffer. All curves were normalized to the elution peak of 
free nucleotide. Relative molecular weights were determined by comparison to 
protein standards.  
 
2.4.5. ATPase assays 
The colormetric assay for monitoring steady-state ATP activity has been 
previously described [44, 45]. Briefly, Hsp70 (1 μM) plus either a J-domain co-
chaperone (DJA2, 0.2 μM) or CHIP (1 μM) was prepared in assay buffer (0.02% 
Triton X-100, 100 mM Tris-HCl, 20 mM KCl, and 6 mM MgCl2, pH 7.4). Protein 
samples were aliquoted into 96-well plates containing 1 mM ATP. After 3h at 
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37°C, malachite green reagent was used to detect liberated phosphate and the 
signal measured on a SpectraMax M5. 
 
2.4.6. Fluorescence quenching assays 
Protein samples were labeled and prepared as previously described [32, 33]. 
Briefly, amine reactive Alex488 (Invitrogen) was used to label Hsp70 and Hsp90 
by mixing the dye and protein at a 10:1 molar ratio in bicarbonate buffer (100 mM 
NaHCO3 [pH 8] containing 150mM NaCl). CHIP was similarly labeled using BHQ-
10 (Biosearch Technologies) at a molar ratio of 50:1, dye: protein. Excess labels 
were removed by passage through Zeba desalting columns (Thermo Scientific) 
equilibrated with HEPES-buffered saline. Using the extinction coefficients 
supplied by the manufacturer, label concentrations were determined for each 
protein sample and used to calculate the amount of molar incorporation. MIR 
values for Hsp70, Hsp90, and CHIP were 3.2, 2.4, and 14.1 respectively. All 
quenching assays were performed at the indicated protein concentrations in 10 
mM HEPES buffer (pH 7.4) containing 150 mM NaCl, and 0.05% Tween-20. 
Equilibrium binding measurements were taken in a 384-well microplate format 
using a SpectraMax M5 microplate reader (Molecular Devices). Each sample 
was excited at 480nm and total fluorescence was read at 525nm with a 515nm 




2.4.7. Ubiquitination assays 
Ubiquitination was typically performed for 1 hr at 37 °C in 10 μL mixtures 
containing buffer A (50 mM Tris pH7.5, 50 mM KCl, 0.2 mM DTT), Ubmix (2.5 
mM ATP, 5 mM MgCl2, 50 nM Ube1 (E1 enzyme), and 100 µM ubiquitin), 1 µM 
UbcH5, 1 µM CHIP, prepared as previously described [46]. Reactions were 
stopped by addition of SDS-Laemmli buffer and boiling, followed by separation of 
proteins by SDSPAGE and visualization by Western blotting with appropriate 
antibodies. Mouse monoclonal antibody to Hsp70 (Assay Designs) was used to 
visualize ubiquitin transfer. 
 
Notes 
The work in this chapter was a collaborative effort and is in the process of being 
published under the title “Characterization of the Binding of the E3 Ubiquitin 
Ligase CHIP to the Molecular Chaperones Hsp70 and Hsp90”. Srikanth Patury, 
Matthew Smith and Jason Gestwicki designed the experiments. Srikanth Patury 
and Andrea Thompson performed the SPR experiments. Matthew Smith 
performed the quenching experiments. And K. Matthew Scaglione ran the 
ubiquitination assays. Srikanth Patury, Matthew Smith and Jason Gestwicki wrote 
the manuscript.  
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2.5. Appendix 
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Improving the synthesis of 15-deoxyspergualin analogs using the  
Ugi multicomponent reaction 
 
3.1. Abstract 
Spergualin is a natural product that exhibits immunosuppressive, anti-tumor and 
anti-bacterial activities. Its derivatives, such as 15-deoxyspergualin (15-DSG), 
have been clinically approved for acute allograft rejection. It binds to the 
molecular chaperone heat shock protein 70 (Hsp70) with low micromolar affinity 
and may provide a promising scaffold from which to build modulators of this 
enzyme. However, with all its promise, the reported syntheses to produce 
spergualin and its derivatives are cumbersome (> 10 steps) and they suffer from 
low overall yields (~ 0.3 to 18%). Moreover, spergualin is chemically unstable 
and it rapidly hydrolyzed in an aqueous environment. To address these 
problems, we have developed a modified synthetic route with significantly 
improved overall yield (~31 to 47%). The key transformation is a microwave-
accelerated Ugi multi-component reaction that is used to generate the α-
acylamino carboxamide core in a single step. Using the products of this route, we 
found that modifications of the hemiaminal significantly increased chemical 
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stability. We also determined that these products maintain some of the anti-
bacterial activity of the natural product. Thus, we anticipate that this synthetic 
route will improve access to biologically active spergualin derivatives. 
 
3.1.1. Spergualin and its derivatives are unstable, yet biologically active, 
polyamines 
The natural product spergualin was first isolated from Bacillus laterosporus, and it 
has gathered significant medical interest because of its potent 
immunosuppressive, anti-tumor and anti-bacterial activities [1-4]. Early 
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characterization revealed that spergualin is composed of three key regions: an α-
acylamino carboxamide (peptoid) core, guanidylated alkyl group and spermidine-
derived polyamine (Figure 3.1) [5] and each of these modules are thought to be 
required for biological activity [2, 6, 7]. However, attempts to further characterize 
the pharmacology of spergualin were complicated by its rapid hydrolysis in 
aqueous buffers. Thus, a major goal of early synthetic efforts was to modify the 
most labile regions, such as the hydroxyl at position 15 and produce a more 
stable analog. 
  
Accordingly, medicinal chemistry studies showed that removing the hydroxyl 
group at the 15 position on the scaffold produced a more potent analog, likely 
due to its increased stability [7]. This product, (-)-15-deoxyspergualin (15-DSG) 
(Figure 3.1), was approved for treatment of acute allograft rejection in renal 
transplant patients [8]. In an effort to understand the mechanism behind the 
immunosuppressive activity of 15-DSG, Nadler et al. demonstrated that the 
compound binds to the constitutively expressed Hsp70 family member Hsc70 
with a dissociation constant (Kd) of 4 μM [9, 10]. 15-DSG produces an Hsc70-
dependent reduction in NF-κB signaling, [11] and it inhibits CD4+ T cell 
maturation [12]. 
 
More recent synthetic efforts have yielded additional derivatives of 15-DSG, such 
as tresperimus (Figure 3.1), in which a portion of the unstable peptoid is 
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replaced with a carbamate [13, 14]. Along with sharing the immunosuppressive 
activity of 15-DSG, tresperimus has also been shown to bind Hsc70, [15] 




Although these derivatives are an improvement on spergualin, they are still 
relatively unstable, with short half-lives (t1/2) in neutral and basic conditions [13]. 
In addition, they are only weakly orally bioavailable (<5%) and metabolized 
rapidly, with terminal half-lives of only 1-2 hours [16]. 
 
3.1.2. The synthesis of spergualin derivatives remains difficult 
One major challenge in the search for improved spergualin derivatives is that the 
reported synthetic routes are cumbersome and low yielding. For example, the 
first attempts produced 15-DSG in only 0.3% yield in more than 10 steps, starting 
from L-lysine and 1-amino-propanol (Figure 3.2A) [2, 6, 17]. Later efforts mildly 
improved the yield of 15-DSG (to ~7% to 18%) by starting with 7-
bromoheptanenitrile and a protected spermidine derivative (Figure 3.2B), but 
these convergent routes remain protracted (> 10 steps) and challenging [18-20]. 
We envisioned an alternative synthetic approach. Specifically, our retrosynthetic 
analysis employs the Ugi multicomponent reaction to assemble the core of 
spergualin in a single step (Figure 3.2C). The Ugi reaction proceeds through the 
condensation of a carboxylic acid, amine, isocyanide, and aldehyde (or ketone. 
[21, 22]. Thus, in addition to the potential advantages gained from the concise 
creation of the peptoid, this route is also expected to allow access to 
combinatorial diversity through varying the identity of the four modules, including 





3.2.1. Optimizing the microwave irradiation-assisted Ugi reaction  
Many conditions for the Ugi reaction have been reported, with the most recent 
studies focusing on the use of microwave irradiation to improve yield and reaction 
times. [23, 24] Guided by these efforts, we first tested the feasibility of the 
approach using the commercially available isocyanide, 1-isocyanopentane, as a 
model reactant. Briefly, an equimolar solution of benyzlamine, benzaldehyde, 6-
guanidinoheptanoic acid, [25] and 1-isocyanopentane was heated in methanol at 
120 °C for 20 minutes in a microwave reactor. These conditions yielded the 
product in good (70%) yield. Encouraged by this observation, we next substituted 
the simple isocyanide with the desired, tert-butyl (4-isocyanobutyl)carbamate (2) 
[26]. Unfortunately, we found that this change dropped the yield to 11%. To solve 
this issue, we re-investigated the reaction conditions, focusing on the variables of 
time, temperature, and solvent (Table 3.1). This approach revealed that the yield 
was particularly sensitive to solvent and that DMF tended to be the best choice 
(average purified yields between 36-46%).  
 
3.2.2. Building a focused library of spergualin analogs 
Using the optimized Ugi conditions (DMF, 100 °C, 20 minutes), we then pursued 
the synthesis of 15-DSG derivatives. Although this reaction is often used in the 
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assembly of large, combinatorial libraries, our first efforts focused on producing a 
small number of focused derivatives to test specific issues related to chemical 
stability (see below). Towards that goal, we combined four aldehydes (3a-d) with 
7-guanidinoheptanoic acid (1), benzylamine, and tert-butyl (4-
isocyanobutyl)carbamate (2) to produce intermediates 4a-d after Boc 
deprotection. In the next step, we envisioned using a reductive amination to 
complete the spermidine module. Towards that goal, we first assembled Fmoc-3-
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amino-1-propanal (5) from Fmoc-β-alanine, using the method of More and Finney 
[27]. Then, compound 5 (0.05 mmol, 1 equiv) was reacted with 4a-d (0.05 mmol, 
1 equiv) in 2 mL THF and NaBH(OAc)3 (0.07 mmol, 1.4 equiv) for 1.5 hours to 
produce intermediates 6a-d. Importantly, NaBH(OAc)3 was chosen for this step 
because, unlike NaBH3CN, it does not require low pH. [28] This was an important 
consideration because of the sensitivity of spergualin analogs to degradation. 
Following the reductive amination, we sought to remove the final protecting 
groups. However, we found that common ways of removing Fmoc, such as 20% 
piperidine in DMF, caused significant hydrolysis. Therefore, we employed the 
alternative, Tris-amine resin (50 equiv) in CHCl3 for 20 minutes [29]. Finally, the 
benzyl group was readily removed under mild conditions using ammonium 
cerium (IV) nitrate (CAN) [30]. Following a final purification by alumina 
chromatography, the products 7a-d were isolated as racemic mixtures in 31 to 
47% overall yield (Figure 3.3).  
 
3.2.3. Spergualin analogs are significantly more stable than the natural 
product 
Having attained our synthetic goals, we wanted to examine the stability of our 
generated analogs in aqueous buffers. As mentioned above, one of the biggest 
challenges in this area is that spergualin and some of its derivatives are prone to 
hydrolysis. Previous studies had suggested that removal of the labile 15-hydroxyl 
group could improve stability [14]. However, Lebreton et al. found that even the 
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clinically approved 15-DSG had a t1/2 of only ~2 hrs in pH 10 buffer [13]. Under 
these conditions, degradation occurs via hydrolysis at the labile hemiaminal 
(Figure 3.4C) [31]. Thus, we reasoned that blocking this degradation route might 
further improve persistence. To test this idea, we first compared the stability of 
spergualin and 11-methoxy-15-deoxyspergualin (7a) using thin layer 
chromatography. Consistent with previous findings, the natural product (Sigma 
Aldrich cat #S5822) is relatively stable under mild acidic conditions (pH 5.0) but it 
is highly unstable in neutral and basic buffers (Figure 3.4A). By comparison, 
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compound 7b, with the methoxy substitution at position 11, had significantly 
improved stability under basic and neutral conditions (Figure 3.4B). Next, we 
quantified the t1/2 values of compounds 7a-d and compared them to those of 
spergualin and 15-DSG. In these studies, we found that the t1/2 values of 
compound 7a at pH 7.0 and 8.0 were 8- and 120-fold greater than spergualin and 
at least 4-fold greater than 15-DSG (Figure 3.4D). More striking, bulky 
substitutions at position 11, as in compound 7b and 7c, markedly improved 
stability to greater than 2 weeks. Together, these results suggest that multiple 
types of substitutions at the hemiaminal could provide significant increases in 
stability under neutral and basic conditions.  
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3.2.4. Spergualin analogs retain antibacterial activity 
To understand whether the introduced substitutions might disrupt bioactivity, we 
tested compounds 7a–d in a series of anti-bacterial assays against Escherichia 
coli, Bacillus subtilis and Staphylococcus aureus. Consistent with previous 
reports, spergualin and 15-DSG had anti-bacterial activity, especially against the 
gram-positive strains [32] (Figure 3.4D). We found that compounds 7a–d 
retained some anti-bacterial activity, although the relative potencies were 
decreased. Of these compounds, 7d appeared the most promising, with good 
activity against B. subtilis and S. aureus. Additional studies are clearly needed to 
understand the relevant structure–activity relationships and to improve compound 
potency. However, these initial efforts show that spergualin analogs with greatly 
improved chemical stability retain some bioactivity. 
 
3.3. Discussion 
3.3.1. The Ugi multicomponent reaction allows increased access to 
spergualin derivatives 
The spergualin scaffold was once seen as a very promising potential therapeutic 
due to its many biological activities. However a long and difficult synthesis, 
coupled to a high rate of hydrolysis have since curbed most of these 
expectations. In part due to spergualins activity towards Hsp70, we wanted to 
reinvestigate these issues. The main hurdle in our eyes was the established 
synthetic routes. We rationalized that if we could improve the synthesis and 
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thereby gain increased access to spergualin derivatives, then tackling hydrolysis 
would be a much easier task. One of the most successful ways to decrease the 
steps in a synthetic route and open a scaffold to derivitization is to develop a 
combinatorial scheme using multicomponent reactions [33]. Applying this method 
to the case of spergualins leads us to the Ugi reaction and the synthetic scheme 
outlined above. Using this synthesis, we were able to produce a small library of 
spergualin analogs with a 2-fold increase in the highest previously published 
yield. Thus we should now be able to produce large derivative libraries of 
spergualin in a more rapid and efficient manner than previously possible.  
 
3.3.2. Spergualin analogs are more stable than and maintain biological 
activity of the natural product 
To reduce the likelihood of hydrolysis at the hemiaminal region of spergualin, we 
synthesized molecules that had the hydroxyl group either masked (7a) or 
replaced with hydrogen (7d) or a bulky substitution (7b-c) at the 11-position. All 
of these substitutions lead to an increased stability of the compound in aqueous 
buffer at a range of pH values. Furthermore, although slightly reduced, in vivo 
anti-bacterial activity persisted in these compounds. Suggesting that these 
modifications to the scaffold did not completely abolish interactions with the 





In this work, an improved method for producing 15-DSG analogs was developed, 
which increased the overall yields by at least 2-fold and greatly reduced the 
number of steps. The key transformation is the Ugi reaction to simultaneously 
generate the peptoid and guanidylated regions. Using this approach, we found 
that substitutions of the hemiaminal significantly improved chemical stability of 
these compounds, which is expected to provide a path towards exploration of 
these compounds as both research probes and therapeutics. Most importantly for 
this thesis work, the revised synthetic route now, for the first time, makes these 
spergualin analogs available for testing as potential inhibitors of the protein-
protein interactions (PPIs) between Hsp70 and TPR-domain co-chaperones. This 
concept will be explored in more detail in Chapter 4. 
 
The next steps to making potent, stable and selective spergualin analogs will be 
to expand upon the library described in the current work, and use these 
compounds to explore the mechanism behind spergualins in vivo activity. 
Currently, another graduate student in the Gestwicki laboratory is expanding our 
collection of spergualin analogs and exploring their structure-activity relationships 





3.4. Materials and methods 
3.4.1. Reagents and general syntheses 
Reagents and solvents were purchased from Sigma and used without further 
purification. All NMR spectra collected on a Varian 400 MHz system.  
 
The synthesis of the known guanidylated amino acid (1) followed a procedure 
reported by Feichtinger, et al. [25] Briefly, a flame-dried round bottom flask 
containing 1 mmol of the 1-heptanoic acid was diluted with 8 mL of anhydrous 
dichloromethane (DCM). Then, N-methyl-N-trimethylsilyl-trifluoroacetamide (2.2 
mmol) was added, and the reaction was heated to reflux under an argon 
atmosphere. Upon clarification of the solution, it was cooled and triethylamine 
(1.1 mmol) and N,Nʼ-di-Boc-Nʼʼ-triflylguanidine (1.1 mmol) were added. The 
reaction was then stirred at room temperature for 4-5 hours, diluted with DCM 
and washed with brine and water. The organic phase was dried with sodium 
sulfate, concentrated and the product purified by column chromatography (eluted 
50:50 ethyl acetate:hexanes). The purified yields ranged from 74-85%.  
  
The preparation of the known isocyanide intermediate (2) followed literature 
precedent [26]. Briefly, 1, 4-diaminobutane (1, 4-DAB; 7.5 g, 85.08 mmol) was 
diluted in 30 mL of dioxane. Then, a solution of di-tert-butyldicarbonate (2.4 g, 11 
mmol) in 30 mL of dioxane was then added drop- wise over 1.5 hours. This 
reaction was stirred for 24 hours and the solvent removed under vacuum. To this 
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mixture, 50 mL of water was added and the resulting insoluble material was 
removed by filtration. The filtrate was extracted three times with 45 mL of DCM. 
The organic layers were dried with sodium sulfate and concentrated to give a 56-
61% yield. Next, the product (2 mmol) was diluted in 5 mL DCM and formic acid 
(2 mmol) was added to the stirring reaction. The reaction was then placed into an 
ice-bath. Once cooled, DIC (2 mmol) was added and the mixture stirred for 4 
hours at room temperature. The reaction was filtered and the filtrate washed with 
saturated sodium bicarbonate. The organic layer was then dried with sodium 
sulfate and concentrated. The resulting product, tert-butyl (4-aminobutyl)-
carbamate, was obtained in 90-92% yield. This product (8.7 mmol) was then 
diluted with 13 mL of DCM, triethylamine (26.2 mmol) was added and the solution 
was cooled in an ice-bath. POCl3 (8.7 mmol) was then added drop-wise. The 
reaction was stirred for 30 minutes, followed by addition of potassium carbonate 
(8.7 mmol). The reaction was then stirred for another 30 minutes and the 
aqueous layer extracted five times with DCM, the organic layers combined, 
washed with water, dried with sodium sulfate, and concentrated. The final 
product was purified by flash column chromatography (eluting at 50:50 ethyl 
acetate: hexanes) giving a 72-76% yield  
 
The synthesis of the known Fmoc-aminopropanal (5) followed the procedure of 
More, and Finney. [27] Briefly, Fmoc-β-alanine (3 mmol, 1 equiv) was added to a 
flame dried round bottom flask and diluted with 20 mL anhydrous DCM. Then, 
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triphenylphosphine (6 mmol, 2 equiv) and trichloroacetonitrile (6 mmol, 3 equiv) 
were added. After the Fmoc-β-alanine appeared to be consumed by TLC, N-O-
dimethyl-hydroxylamine hydrochloride (6.3 mmol, 2.1 equiv) and pyridine (15 
mmol, 5 equiv) were added at 0 °C. After 1 hour, the reaction was washed with 
brine and dried over sodium sulfate. After concentration, the product, N-methoxy-
N-methyl-3-(Fmoc-amino)-propionamide, was purified by flash column 
chromatography (eluting at 50:50 ethyl acetate:hexanes) to give a 97% yield. 
Next, the N-methoxy- N-methyl-3-(Fmoc-amino)-propionamide (1.15 mmol, 1 eq) 
was dissolved in 10 mL anhydrous THF. The reaction was cooled to -78 °C under 
argon and 3.45 mL of a 1.0 M solution of diisobutylaluminum hydride (3 equiv) in 
THF was added drop-wise over 10 minutes. After 5 minutes the reaction was 
quenched with 5% HCl in EtOH, and allowed to warm to room temperature. This 
solution was diluted into DCM and washed with brine. The organic layers were 
sodium sulfate and then concentrated under vacuum. The product was then 
purified by flash column chromatography (eluting with 50:50 ethyl 
acetate:hexanes) to afford Fmoc-3-amino-1-propanal in 62% yield. 1H NMR 
(CDCl3): δ 9.83 (1H, s), 7.78 (2H, d), 7.60 (2H, d), 7.33 (4H, m), 5.3 (1H, bs), 






3.4.2. Spergualin analog syntheses 
The Ugi reaction was performed by mixing benzylamine (0.1 mmol), an aldehyde 
(3a-e; 0.1 mmol), 6-guanidinohexanoic acid (1; 1.1 mmol), and tert-butyl (4-
isocyanobutyl)carbamate (2; 0.1 mmol) in 0.5 mL DMF. This reaction was heated 
to 100 °C for 20 minutes in a Biotage Initiator EXP microwave reactor. The 
products were treated with phosphoric acid and purified on silica. Each product 
(0.05 mmol, 1 equiv) was reacted with compound 5 (0.05 mmol, 1 equiv) in 2 mL 
THF and NaBH(OAc)3 (0.07 mmol, 1.4 equiv) for 1.5 hours. The reactions were 
quenched with saturated sodium bicarbonate, the products extracted into ethyl 
acetate and purified on basic alumina oxide, eluting with 10:90 methanol:ethyl 
acetate. The remaining Fmoc groups were removed with 30 equiv of Tris-amine 
resin (Biotage) at room temperature. Finally, the benzyl group was removed by 
adding CAN (2.1 equiv) in a solution of 1:5 water:acetonitrile (2 mL). After stirring 
for 2 hours, the reaction was quenched with saturated sodium bicarbonate, 
stirred for 10 minutes and extracted with ethyl acetate. The organic layers were 
combined, dried over sodium sulfate and concentrated under vacuum. The 
product was then purified on basic alumina oxide (eluting at 10:90 methanol:ethyl 




guanidinoheptanamide (7a). 13C NMR (100 MHz, methanol-d6) 174.9, 166.1, 
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157.1, 91.3, 55.7, 53.0, 51.2, 46.9, 40.4, 39.8, 39.0, 37.3, 32.3, 28.5, 27.3, 26.8, 
26.1, 24.7; 1H NMR (CDCl3) δ 8.16 (2H, s), 5.84 (1H, s), 4.61-4.38 (2H, d), 4.10- 
3.75 (2H, d), 3.31 (3H, d), 3.13 (2H, s), 2.70 (6H, s), 2.32-2.03 (8H, m), 1.64-1.51 
(10H, m) 1.25-1.14 (4H, m). HPLC purity 90%  
 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(4-bromophenyl)-2- oxoethyl)-7-
guanidinoheptanamide (7b). 13C NMR (100 MHz, methanol-d6) 170.5, 168.2, 
157.1, 137.8, 133.3, 133.7, 129.9, 129.6, 121.9, 57.9, 53.0, 51.2, 46.9, 40.5, 
39.8, 39.5, 37.3, 32.1, 28.5, 27.3, 26.6, 26.1, 24.6; 1H NMR (CDCl3)δ 8.16 (2H, 
s), 7.79 (2H, d), 7.51 (2H, d), 5.82 (1H, s), 4.56-4.18 (4H, m), 4.15 (2H, s), 3.20 




guanidinoheptanamide (7c). 1H NMR (CDCl3)δ 8.14 (2H, s), 7.67 (2H, m), 7.29 
(2H, m), 7.10 (1H, m), 6.09 (1H, s), 5.82 (2H, s), 4.99 (1 H, s), 4.59 (2H, s), 4.38 
(2H, d), 3.32-3.21 (4H, m), 3.12 (2H, d), 2.32 (1H, t), 2.05 (1H, s), 1.62-1.55 (8H, 
m), 1.52-1.41 (10H, m), 1.25 (2H, s), 1.12 (2H, s), 0.86 (2H, s). HPLC purity 80%  
 
N-(1-((4-((3-aminopropyl)amino)butyl)amino)-1-oxo-4-phenylbutan-2-yl)-7- 
guanidinoheptanamide (7d). 13C NMR (100 MHz, methanol-d6) 175.5, 169.5, 
157.1, 52.3, 49.4, 48.6, 46.9, 40.4, 39.5, 38.7, 37.3, 32.3, 28.5, 27.3, 26.8, 26.1, 
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24.7; 1H NMR (CDCl3) δ 5.92 (1H, s), 4.61-4.57 (2H, d), 3.86-3.84 (2H, d), 3.60 
(1H, s), 3.16-3.02 (8H, m), 2.38-2.35 (t, 2H), 2.28-2.24 (t, 1H), 1.97 (s, 1H), 1.61-
1.53 (6H, m), 1.46-1.17 (8H, m), 0.86 (2H, s). HPLC purity 82%  
 
3.4.3. High performance liquid chromatography 
HPLC analysis for purity was performed using a Waters Spherisorb ODS2 
analytical column (4.6x250mm), mobile phase: 5-80% ACN in water, sample 
load: 1 mg in 500 µL DMSO, flow rate: 2 mL/min, detection: 218 nm UV.  
  
3.4.4. Thin-layer chromatography 
The chemical stability of the spergualin derivatives was estimated by monitoring 
the integrity of the products by TLC. We found that this approach was better able 
to identify certain degradation products than HPLC. Briefly, compounds 7a-d or 
spergualin were first suspended in dimethyl sulfoxide at a concentration of 20 
mM, then diluted to 1 mM in aqueous buffer. Aliquots (~1 µL) were spotted on 
silica TLC plates and developed in a solvent mixture of butanol, water, pyridine, 
and acetic acid (3:2:1:1 v/v). Products were visualized with ninhydrin. The plates 
were then immediately scanned and the images quantified with NIH Image J. 






This work has been published as “Improved synthesis of 15-deoxyspergualin 
analogs using the Ugi multi-component reaction” Bioorganic & Medicinal 
Chemistry Letters, 2011. 21(9): p. 2587-2590. Chris Evans and Jason Gestwicki 
designed the revised spergualin synthesis. Chris Evans and Matt Smith 
performed the experiments. JP Carolan helped with the syntheses and anti-
bacterial assays. Chris Evans, Matt Smith and Jason Gestwicki analyzed the 
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The molecular chaperone Hsp70 sits at a critical junction in protein homeostasis. 
Through concerted interactions with a number of co-chaperones, Hsp70 can 
promote either the stability or degradation of its client proteins. There is growing 
interest in using chemical probes to better understand the specific roles played 
by Hsp70ʼs co-chaperones. Here, we describe an analog of the natural product 
spergualin that inhibits binding of Hsc70 to the co-chaperone, C-terminus of 
Hsc70 interacting protein (CHIP), an E3 ubiquitin ligase involved in degradation 
of Hsc70 clients. This compound directly blocked the protein-protein interaction 
between Hsc70 and CHIP in vitro and it caused accumulation of the Hsc70 client 
protein, tau, in cells. This work provides the first small molecule inhibitor of the 





4.1.1. Protein-protein interactions in the Hsp70 system 
As discussed briefly in Chapter 1, Heat-shock protein 70 (Hsp70) is an essential 
and ubiquitous molecular chaperone that protects the proteome by binding to 
exposed hydrophobic regions in unfolded proteins [1, 2]. In this task, Hsp70 
relies on a number of co-chaperone proteins, which are divided into three classes 
based on their functionality and mode of binding to Hsp70. Members of the J-
domain superfamily of co-chaperones have the dual function of presenting 
protein substrates to Hsp70 and facilitating hydrolysis of ATP, thereby increasing 
affinity for substrate [3]. Nucleotide exchange factors (NEFs) potentiate the 
release of ADP and subsequent substrate release [4, 5]. Finally, tetratricopeptide 
repeat (TPR) domain-containing proteins are thought to bind to Hsp70 and 
dictate the fate of the bound substrate, facilitating either protein refolding or 
degradation [6, 7]. Though recent studies have elucidated how these TPR 
proteins bind Hsp70 [8], the mechanism of how they arbitrate between these two 
very important but dichotomous paths remains completely unresolved.  
 
4.1.2. The C-terminus of Hsp70 acts as a hub for TPR protein binding 
The TPR domain is a common motif that facilitates protein-protein interactions in 
a wide range of organisms, from bacteria to humans [9]. The structure of the 
domain consists of multiple repeats of a degenerate 34 amino acid consensus 
sequence that forms a basic helix-turn-helix fold [8]. These repeats assemble into 
anti-parallel α helices with an overall super-helical structure and ligands typically 
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bind to the concave surface of this super-helix. These ligands of TPR domains 
are often short, elongated peptide sequences [10]. For example, the last four 
amino acids of Hsp70 (EEVD) have been shown to bind to the TPR domain of 
the co-chaperone Hop (Hsp70/90-organizing protein) [8]. And, as mentioned in 
Chapter 2, the EEVD motif has been shown by our group to account for ~80% of 
the binding affinity for the Hsp70-CHIP interaction.  
 
Through this EEVD-TPR interaction, Hsp70 recruits TPR-domain co-chaperones 
that are essential for carrying out chaperone functions. For example, CHIP links 
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Hsp70 and its substrates to the proteasome, while HOP allows for the transfer of 
substrates to the Hsp90 system for further folding (Figure 4.1) [11]. Furthermore, 
it has been well established that only one TPR-domain co-chaperone can bind to 
Hsp70 at a time [6, 7, 12] suggesting that this interaction may represent a critical 
step in the triage decision process. Because this protein-protein interaction (PPI) 
is a nexus for Hsp70 biology, it has drawn considerable interest among chemical 
biologists as a point for chemical intervention [13, 14]. However, there are few 
small molecule inhibitors of the TPR interaction and their mechanisms remain 
unclear. The goal of this Chapter is to determine whether spergualin analogs 
might serve as a new chemical scaffold for building inhibitors of this important 
PPI. 
 
4.1.3. Spergualin analogs bind to the C-terminus of Hsp70 
Spergualin is a natural product produced by Bacillus laterosporus, which was 
originally found to have antitumor and antibiotic activity [15]. Early structural 
efforts revealed that spergualin is a polyamine-derived natural product [16] and 
structure-activity studies produced 15-deoxyspergualin (15-DSG) [17], which has 
superior stability. Subsequent efforts showed that 15-DSG has potent 
immunosuppressive activity [18], and this compound was granted clinical 
approval for the treatment of acute allograft rejection in Japan [19]. Target 
identification studies suggested that 15-DSG binds to Hsp70 [20] and further 
mass spectrometry and crosslinking studies suggested that the likely binding site 
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is in the C-terminal EEVD motif [21]. Because of the importance of the EEVD 
motif in binding TPR domain proteins (Chapter 2), we considered it possible that 
this compound might block the protein-protein interacton (PPI) between Hsp70 
and its TPR co-chaperones. To allow these inquiries, we described (in Chapter 3) 
an improved synthesis of spergualin analogs. In this Chapter, we deploy these 
analogs to test whether this scaffold inhibits the Hsp70-CHIP interaction. 
 
4.2. Results 
4.2.1. A spergualin analog inhibits binding of Hsp70 to CHIP  
In a previous study (Chapter 2), we developed a fluorescence-quenching assay 
to characterize the interaction between CHIP and Hsc70 (the constitutively 
expressed isoform of the Hsp70 family). In this assay, the quenching of a 
fluorophore is measured upon mixing of labeled Hsc70 and CHIP (Figure 4.2). 
The apparent Kd for the Hsc70-CHIP interaction was calculated to be 76 ± 11 nM 
(Figure 4.2A). We therefore used this assay to test spergualin analogs for the 
ability to inhibit this PPI. As a first test of this idea, we incubated labeled Hsc70 
(0.05 µM) and CHIP (0.08 µM) with compound 1, a spergualin analog that has 
been reported to bind Hsc70 [22]. This compound weakly (IC50 = 131 ± 13 μM) 
inhibited the Hsc70-CHIP interaction (Figure 4.2B), suggesting for the first time, 
that spergualin analogs can inhibit the binding of Hsc70 to a TPR co-chaperone. 
 
Next, we tested which regions of spergualin might be important for this activity. 
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Previous attempts to acquire structure-activity relationships (SAR) in the 
spergualin series relied primarily on data from murine models, such that 
pharmacokinetics and metabolic stability would contribute to the apparent SAR. 
We wanted to re-explore this issue using our in vitro assay to generate SAR 
focused more directly on the inhibition of the Hsc70-CHIP PPI. Our initial studies 
revealed that the α-acylamino carboxamide core is essential for activity, as 
neither side of the core, 7-gaunidinoheptanoic acid nor spermidine, in isolation, 
show significant inhibition (IC50's >> 500 μM; Figure 4.2B). 
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4.2.2. Screen of spergualin library reveals a potent inhibitor 
Guided by these initial findings, we expanded the chemical series of spergualin 
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analogs and tested them in the fluorescence assay (Table 4.1). We focused this 
series on varying the 11-position and varying the lengths of the regions adjacent 
to the carboxamide core,  because early studies suggested that these positions 
are important for in vivo activity. From the IC50 values of the compounds in this 
series, it appears that adding bulk to the 11-position (compounds 5a-e and 9) 
significantly increased potency. Further, with these bulky substitutions, the full 
spermidine moiety was dispensable for activity (compare compounds 4b, 4d to 
5b, 5d). The most potent compounds were 5b and 5d, which both have the 11-
position (4-Bromo)-phenyl substitution and an IC50 value of ~10 μM. These 
compounds were approximately 10-fold more potent than the initial compound 1 
(Figure 4.2C). Thus, we decided to use compound 5b to further explore the 
mechanism of spergualin activity on the Hsc70-CHIP interaction. 
 
4.2.3. Spergualin analog disrupts the Hsc70-CHIP interaction by size-
exclusion chromatography  
To confirm the inhibitory activity seen in the quenching assay, we explored 
whether compound 5b could disrupt the Hsc70-CHIP complex by gel filtration. 
The elution pattern of Hsc70 alone, and in complex with CHIP is shown in Figure 
4.3A. At a 2:1 molar ratio for Hsc70:CHIP, approximately half of the Hsc70 was in 
complex with CHIP, and so we used this molar ratio to characterize compound 
administration. Because the protein concentration in the gel filtration platform is 
40 fold higher than what was used in the fluorescence quenching assay, we 
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increased the compound concentration to 500 μM and tested for inhibition. 
Compound 5b showed a clear decrease in the amount of complex formation 
when compared to a DMSO control or administration of a negative control 
compound spermidine (Figure 4.3B). Compound 5d showed a very similar effect 
at the same concentration (Figure 4.3C). Taken together, these data confirm that 
spergualin analogs inhibit binding of Hsc70 to CHIP. 
 
4.2.4. The effect of Spergualin analogs on other Hsp70 PPIs 
Spergualin analogs have been shown to modestly inhibit single-turnover ATP 
hydrolysis of Hsc70 in the presence of a J domain co-chaperone [23]. Thus, we 
wanted to test whether compound 5b might disrupt the binding of a J protein. 
Using our quenching assay to monitor the interaction of the prokaryotic Hsp70, 
DnaK, to its J protein co-chaperone, DnaJ, (Appendix 4.5.1), we found that 
compound 5b had no effect on this PPI (IC50 > 500 µM; Figure 4.4A). In contrast, 
the small molecule myricetin, has been shown to be a potent inhibitor of DnaK-
DnaJ interactions in this assay [24]. 
 
Next, we tested whether spergualin analogs would impact the ATPase activity of 
Hsp70 using a well known malachite green (MG) assay [25, 26]. This assay 
measures the stimulation of Hsc70 ATPase activity by J protein co-chaperones. 
Consistent with previous reports of 15-DSGʼs activity towards Hsc70 [23], none of 
the compounds tested had any effect on the ATPase activity of Hsc70 stimulated 
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by a purified J domain (Figure 4.4B). These data suggest that spergualin 
analogs block the Hsc70-CHIP interaction but they do not effect ATP turnover or 
interactions with J proteins. 
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Due to the mutually exclusive manner in which TPR proteins have been shown 
bind to Hsc70, we decided to investigate whether compound 5b might disrupt 
other Hsc70-TPR interactions. In order to accomplish this, we adapted the 
fluorescence quench assay to monitor the binding between Hsc70 and Hop 
(Hsp70-90 organizing protein) and the immunophilin FKBP51. Both proteins 
show moderate affinity for Hsc70 having similar apparent Kdʼs (~140 μM) 
(Appendix 4.5.1). Compound 5b inhibited both interactions, with IC50 values in 
the mid-micromolar (22 ± 1.0 and 18 ± 2.0 μM respectively; Figure 4.4C-D). This 
is very similar to the potency of this compound towards inhibiting Hsc70-CHIP, 
suggesting that it is a pan-inhibitor of Hsc70-TPR PPIs.   
 
4.2.5. Spergualin binds the C-terminus of Hsc70  
To gain further mechanistic information about how spergualin analogs might 
block the EEVD-TPR interaction, we explored the binding of compound 5b to 
Hsc70 by NMR. Guided by the previous studies using mass spectrometry, we 
focused on the C-terminal region of Hsc70 (residues 391 to 647). This region 
includes the beta-sandwich domain, which binds to Hsc70 substrates and the 
“lid” region, which contains the EEVD motif. 15N TROESY NMR spectra were 
recorded of this construct in phosphate buffer (150 mM NaCl, 50 mM sodium 
phosphate, pH = 7) at 200 µM. Assignment of this construct is still ongoing, but 
we observed a clearly defined region consistent with the beta sandwich domain 
and a more flexible region consistent with the lid. Titration of compound 5b into 
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this system revealed a number of discrete chemical shift perturbations (data not 
shown), with the most dramatic shifts in the lid and a few shifts in the beta-
sandwich. Although definition of this binding site awaits assignment of the 
spectra, these results strongly support the idea that the spergualin scaffold binds 
to the C-terminus of Hsc70. 
 
4.2.6. Spergualin analog inhibits the Hsp70-TPR interactions in cells 
Having established that compound 5b inhibited Hsc70-TPR interactions in vitro, 
we next wanted to investigate whether this effect was maintained in the more 
complex environment of the cell. To test this idea, we transiently transfected 
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HeLa cells with HA-tagged constructs of either CHIP, HOP or FKBP51 (Figure 
4.5A). We then performed co-immunoprecipitation experiments using Sepharose-
immobilized anti-HA antibody and probed for the presence of Hsc70 (Figure 
4.5B). This experiment confirmed that Hsc70 binds these TPR co-chaperones in 
HeLa cells. Tests using the spergualin analogs are ongoing, but we expect that 
they will reduce the levels of precipitated Hsc70, which would confirm inhibition of 
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the Hsc70-TPR interaction.  
 
4.2.7. Inhibition of the Hsc70-CHIP interaction in cells causes Tau 
accumulation 
One of the important cellular targets of the Hsc70-CHIP complex is the 
microtubule-associated protein tau (MAPT; tau) [27]. For example, depletion of 
CHIP elevates tau levels in both a HeLa cell model of tau overexpression and 
mouse brain homogenates [27, 28]. Thus, we reasoned that spergualin analogs 
might elevate tau levels in cells, if they block CHIP function by inhibiting the 
Hsc70-CHIP PPI. Consistent with this idea, compound 5b increased tau levels in 
these cells with an EC50 value of approximately 5 µM (Figure 4.6A), Compound 
1 also showed modest activity in this assay (Appendix 4.5.2), whereas 
spermidine had no effect (Figure 4.6C). Interestingly, compound 5d, which lacks 
the full polyamine portion of the molecule, also did not have any activity in the cell 
culture model (Figure 4.6B). Because this compound had activity in vitro, this 
result suggests that the spermidine moiety may be required for membrane 
permeability [29]. These studies suggest that spergualin analogs capable of 




4.3.1. Rational design of a novel Hsc70 inhibitor  
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Due to its central role in Hsc70 substrate processing, the Hsc70-TPR PPI has 
become a promising target for modulating chaperone activity. However, progress 
towards inhibitors of this interaction is in its early stages. One promising scaffold 
is 15-DSG, because spergualin analogs have been shown to bind the EEVD 
motif of Hsc70 and this compound targets the Hsc70 complex [30]. Using a newly 
developed synthetic route, we produced a small library of spergualin analogs and 
found that they could indeed inhibit the interaction between Hsc70 and CHIP, 
using either a fluorescence assay, gel filtration or an NMR experiment. In this 
chemical series, we found that substituting the 11-position with significant bulk 
  109 
significantly improved potency, resulting in compounds 5b and 5d. These 
compounds appear to block the Hsc70-TPR interaction in cells, because 
compound 5b caused the accumulation of the Hsc70-CHIP client protein, tau.  
 
Taken together, these data suggest that spergualin derivatives are promising 
inhibitors of the PPI between Hsc70 and TPR co-chaperones. Notably, this 
inhibitory effect is not limited to CHIP. Rather, interactions with both HOP and 
FKBP51 were also sensitive. An interesting future direction will be building 
selectivity into the spergualin scaffold, a task that will be made much more 
amenable once binding site information is available.  
 
4.3.2. Re-investigating a promising chemical scaffold 
One of the other interesting conclusions of this study is that spergualins might 
possess biological activity, in part, due to their activity at the Hsp70-TPR 
interface. It has been over 20 years since the first successful clinical trial 
involving the spergualin derivative 15-DSG was published [19, 31]. And yet, there 
has been surprisingly little mechanistic understanding as to how 15-DSG 
functions at a biochemical level. Spergualin analogs have been reported to have 
anti-tumor, immunosuppressive, anti-infective and anti-malarial activity [15, 32-
34]. How can this compound impact so many different systems? One possibility 
is that some or all of these biological responses might arise from inhibition of 
Hsp70 PPIs. This speculative model remains untested. However, the studies 
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provided here, in combination with the results in Chapter 2 and 3, provide a 
framework for developing potent inhibitors of Hsp70-TPR interactions.  
 
4.3.3. Conclusions 
This work describes the discovery of the first well-characterized inhibitor of the 
Hsc70-TPR interaction and establishes the framework for using the spergualin 
scaffold to probe the roles of this PPI in protein homeostasis. Even with the lack 
of specificity, compound administration caused the accumulation of the client 
protein, tau, in cellular assays. This remarkable result suggests that some Hsc70 
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clients (i.e. tau) may have dedicated TPR proteins (i.e. CHIP) that preferentially 
mediate their fate (Figure 4.7). Thus, the current study provides a foundation 
from which to build more selective and potent inhibitors to continue to probe this 
important PPI. Strategies for achieving this goal are discussed in detail in 
Chapter 5. 
 
4.4. Materials and methods 
4.4.1. Reagents and general syntheses 
Reagents and solvents were purchased from Sigma-Aldrich and used without 
further purification. All NMR spectra were collected on a Varian 400 MHz system.  
The syntheses for all starting materials have been previously described [35]. 
Briefly, guanidylated amino acid was prepared from the condensation of either (1 
mmol) 1-aminoheptanoic, 1-aminohexanoic, or 1-aminobutanoic acid and (1.1 
mmol) N,Nʼ-di-Boc-Nʼʼ-triflylguanidine, followed by purification by flash 
chromatography [36]. The isocyanide intermediate was made via reduction of the 
carbamate moiety generated from either 1,4-diaminobutane or p-
phenylenediamine using 1 equivalent POCl3 in dry dichloromethane [37] and 
subsequent purification via flash chromatography. Finally, the synthesis of the 
known Fmoc-aminopropanal followed the procedure of More and Finney [38]. 
This synthesis is accomplished by the reduction of Fmoc-β-alanine to its 
corresponding aldehyde using diisobutylaluminum hydride and purification by 
flash chromatography.                                                 
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4.4.2. Spergualin analog syntheses 
Full details of the spergualin synthesis has been published elsewhere [35]. For 
the molecules described in this study, the Ugi reaction was performed by mixing 
benzylamine (0.1 mmol), an appropriate aldehyde (0.1 mmol), guanidylatedamino 
acid (1.1 mmol), and tert-butyl (4-isocyanobutyl)carbamate or tert-butyl (4-
isocyanophenyl)carbamate (0.1 mmol) in 0.5 mL DMF. This reaction was heated 
to 100 °C for 20 minutes in a Biotage Initiator EXP microwave reactor. The 
products were deprotected with phosphoric acid, followed by neutralization to pH 
7 with 10% NaOH and purification on basic alumina oxide. Each product (0.05 
mmol, 1 equiv) was either reacted with Fmoc-aminopropanal (0.05 mmol, 1 
equiv) in 2 mL THF and NaBH(OAc)3 (0.07 mmol, 1.4 equiv) for 1.5 hours or 
deprotected completely to the final product. The reactions were quenched with 
saturated sodium bicarbonate, the products extracted into ethyl acetate and 
purified on basic alumina oxide, eluting with 10:90 methanol:ethyl acetate. The 
remaining Fmoc groups were removed with 30 equiv of Tris-amine resin 
(Biotage) at room temperature. Finally, the benzyl group was removed by adding 
Ceric ammmonium nitrate (2.1 equiv) in a solution of 1:5 water:acetonitrile (2 
mL). After stirring for 2 hours, the reaction was quenched with saturated sodium 
bicarbonate, stirred for 10 minutes and extracted with ethyl acetate. The organic 
layers were combined, dried over sodium sulfate and concentrated under 
vacuum. The product was then purified on basic alumina oxide (eluting at 10:90 
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methanol:ethyl acetate) to afford the final products. The overall purified yields 
ranged from 31-47%. 
 
4.4.3. Characterization of spergualin analogs 
N-(1-((4-((3-aminopropyl)amino)butyl)amino)-1-oxo-4-phenylbutan-2-yl)-7- 
guanidinoheptanamide (1). 13C NMR (100 MHz, methanol-d6) 175.5, 169.5, 
157.1, 52.3, 49.4, 48.6, 46.9, 40.4, 39.5, 38.7, 37.3, 32.3, 28.5, 27.3, 26.8, 26.1, 
24.7; 1H NMR (CDCl3) δ 5.92 (1H, s), 4.61-4.57 (2H, d), 3.86-3.84 (2H, d), 3.60 
(1H, s), 3.16-3.02 (8H, m), 2.38-2.35 (2H, m), 2.28-2.24 (1H, s), 1.97 (1H, s), 
1.61-1.53 (6H, m), 1.46-1.17 (8H, m), 0.86 (2H, s).  
N-(1-((4-((3-aminopropyl)amino)butyl)amino)-1-oxopropan-2-yl)-4-
guanidinobutanamide (2a). 1H NMR (CDCl3) δ 8.15 (2H, s), 6.06 (1H ,s), 4.58 
(2H, s), 4.22 (2H, s), 3.33 (4H, d), 3.11 (6H, s), 2.72-2.46 (5H, m), 1.52 (4H, s), 
1.45 (5H, d), 1.11 (2H, d).  
N-(1-((4-((3-aminopropyl)amino)butyl)amino)-1-oxopropan-2-yl)-6-  
guanidinohexanamide  (2b): 1H NMR (CDCl3) δ 8.16 (2H, s), 5.82 (1H ,s), 4.60 
(2H, s), 4.38 (2H, s), 3.31 (4H, d), 3.13 (6H, s), 2.67-2.52 (5H, m) 1.65-1.53 (6H, 
m), 1.14 (4H, d), 0.83 (5H, d).  
N-(1-((4-((3-aminopropyl)amino)butyl)amino)-1-oxopropan-2-yl)-7-
guanidinoheptanamide (2c): 1H NMR (CDCl3) δ 8.03 (2H, s), 5.11 (1H ,s), 4.77 
(2H, s), 4.51 (2H, s), 3.20 (4H, d), 2.87-2.55 (8H, s), 2.05 (3H, m), 1.85-1.69 (8H, 
m), 1.14 (4H, d), 0.83 (5H, d).  
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N-(4-((3-aminopropyl)amino)butyl)-2-(4-guanidinobutanamido)-4-
phenylbutanamide (3a): 1H NMR (CDCl3) δ 8.13 (2H, s), 7.36 (2H, m), 7.24-7.17 
(3H, m), 6.06 (1H, s), 4.67 (3H, m), 3.31 (4H, d), 3.11 (4H, d), 2.55-2.46 (8H, m), 
1.52 (4H, m), 1.39-1.11 (8H, m). 
N-(1-((4-((3-aminopropyl)amino)butyl)amino)-1-oxo-4-phenylbutan-2-yl)-6-
guanidinohexanamide (3b): 1H NMR (CDCl3) δ 8.02 (2H, s), 7.51 (2H, m), 7.34-
7.29 (3H, m), 6.19 (1H, s), 4.83 (3H, m), 3.52 (4H, d), 3.22 (4H, d), 2.67-2.51 
(8H, m), 1.67 (4H, m), 1.41-1.29 (12H, m). 
N-(1-((4-((3-aminopropyl)amino)butyl)amino)-1-oxo-4-phenylbutan-2-yl)-7-
guanidinoheptanamide (3c): 1H NMR (CDCl3) δ 8.19 (2H, s), 7.42 (2H, m), 7.29-
7.14 (3H, m), 6.08 (1H, s), 4.56 (3H, m), 3.23 (4H, d), 3.15 (4H, d), 2.54-2.46 
(8H, m), 1.79 (4H, m), 1.52-1.41 (10H, m). 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-methoxy-2-oxoethyl)-4-  
guanidinobutanamide (4a): 1H NMR (CDCl3) δ 8.16 (2H, s), 5.87 (1H, s), 3.32 
(3H, s), 3.13 (2H, s), 1.54 (8H, m), 1.49 (10H, s). 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-methoxy-2-oxoethyl)-6-
guanidinohexanamide (4b): 1H NMR (CDCl3) δ 8.21 (2H, s), 5.89 (1H, s), 4.43 
(1H, d), 4.32 (2H, d), 3.25 (2H, m), 3.03 (3H, s), 1.47 (12H, m), 1.18 (10H, m). 
N-(2-((4-aminobutyl)amino)-1-methoxy-2-oxoethyl)-6-guanidinohexanamide (4d): 
1H NMR (CDCl3) δ 8.09 (2H, s), 5.88 (1H, s), 4.32 (3H, d), 3.41-3.06 (6H, d), 
2.26 (2H, s), 1.41 (6H, m), 1.19-1.06 (4H, m).  
N-(2-((4-((3-aminopropyl)amino)phenyl)amino)-1-methoxy-2-oxoethyl)-6-  
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guanidinohexanamide (4e): 1H NMR (CDCl3) δ 8.28 (2H, s), 7.47 (2H, d), 7.34-
7.30 (2H, d), 5.82 (1H, s), 4.50 (2H, d), 3.49 (2H, m), 2.04 (1H, s), 1.74 (4H, m), 
1.51 (4H, d), 1.26 (4H, s), 0.84 (2H, d). 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(4-bromophenyl)-2-oxoethyl)-4-  
guanidinobutanamide (5a): 1H NMR (CDCl3) δ 8.17 (2H, s), 7.77-7.58 (2H, d), 
7.40- 7.31 (2H, d), 5.87 (1H, s), 4.63 (2H, s), 3.33 (2H, s), 3.14 (2H, s), 1.55 (4H, 
s), 1.44 (10H, s), 1.15 (2H, d).  
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(4-bromophenyl)-2-oxoethyl)-6-  
guanidinohexanamide (5b): 1H NMR (CDCl3) δ 8.16 (2H, s), 7.34-6.98 (4H, m), 
5.67 (1H, s), 4.68-4.52 (2H, m), 4.49 (2H, s), 3.31-3.06 (4H, dd), 2.43 (2H, m), 
2.03 (2H, s), 1.70 (4H, s), 1.48-1.41 (10H, m), 1.13 (4H, d).   
N-(2-((4-aminobutyl)amino)-1-(4-bromophenyl)-2-oxoethyl)-6-
guanidinohexanamide (5d): 1H NMR (CDCl3) δ 8.03 (2H, s), 7.81-7.69 (2H, d), 
7.63-7.57 (2H, d), 5.82 (1H, s), 4.42 (2H, s), 4.04 (2H, s), 3.41-2.98 (4H, m), 
2.25-2.17 (2H, m), 1.97 (2H, s), 1.42 (4H ,m), 1.20 (4H, m), 0.86 (2H, d).  
N-(2-((4-((3-aminopropyl)amino)phenyl)amino)-1-(4-bromophenyl)-2-oxoethyl)-6-
guanidinohexanamide (5e): 1H NMR (CDCl3) δ 8.28 (2H, s), 7.43-7.39 (4H, d), 
7.34-7.30 (2H, d), 6.68 (2H, d), 5.12 (1H, s), 4.39 (2H, d), 3.35 (2H, m), 2.65 (2H, 
s), 1.83 (4H, m), 1.52 (2H, d), 1.29 (4H, s). 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(3,5-dimethoxyphenyl)-2-
oxoethyl)-6-guanidinohexanamide (6): 1H NMR (CDCl3) δ 8.16 (2H, s), 7.34-6.98 
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(4H, m), 5.67 (1H, s), 4.68-4.52 (2H, m), 4.49 (2H, s), 3.31-3.06 (4H, d), 2.43 
(2H, m), 2.03 (2H, s), 1.70 (4H, s), 1.48-1.41 (10H, m), 1.13 (4H, d). 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(3-hydroxyphenyl)-2-oxoethyl)-6-
guanidinohexanamide (7): 1H NMR (CDCl3) δ 8.03 (2H, s), 7.71 (1H, s), 7.36-
7.26 (2H, m), 6.83 (1H, s), 5.82 (1H, s), 4.31-4.22 (2H, d), 3.30 (2H, m), 3.09-
2.92 (4H, d), 2.55 (10H, s), 1.41 (14H, s), 1.27 (2H, s). 
 N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(3,5-dimethoxyphenyl)-2-
oxoethyl)-6- guanidinohexanamide (8): 1H NMR (CDCl3) δ 8.16 (2H, s), 7.53-
7.06 (3H, s), 5.88 H NMR (CDCl3) δ 8.16 (2H, s), 7.34-6.98 (4H, m), 5.67 (1H, s), 
4.68-4.52 (2H, m), 4.49 (2H, s), 3.31-3.06 (4H, d), 2.43 (2H, m), 2.03 (2H, s), 
1.70 (4H, s), 1.48-1.41 (10H, m), 1.13 (4H, d). 
N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-(4-(benzyloxy)phenyl)-2-
oxoethyl)-6-guanidinohexanamide (9): 1H NMR (CDCL3) δ 8.13 (2H, 2), 7.47-
7.32 (4H, m), 7.21 (2H, d), 7.01 (2H, d), 6.08 (1H, s), 5.52 (2H, s), 4.57 (2H, s), 
3.21 (2H, d), 3.14 (4H, d), 2.13 (4H, m), 1.72 (2H, d), 1.56-1.44 (10H, m), 1.08 
(4H, d). 
 
4.4.4 Protein purification 
All Hsc70 proteins were derived from the human Hsc70 (HSPA8). All Hsc70, 
Hsc70 SBD truncations, DnaK, HOP, FKBP51, DnaJ, and J-domain sequences 
were cloned into the pMCSG7 plasmid (Midwest Center for Structural Genomics, 
Bethesda, MD) by ligation independent cloning and transformed into Rosetta 
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(DE3) cells for expression. For expression, 25 mL of overnight (37 °C) LB culture 
of Rosetta (DE3) culture was poured into 1 L of Terrific Broth. After 3 hours 
incubation at 37 °C, the culture was cooled down to 16-28 °C for 2 hours before 
overnight induction of expression with 200-500 µM IPTG, and the cell pellet was 
stored at -80 °C until use. For 15N labeling of Hsc70 SBD, the 25 mL overnight LB 
starter culture was first rinsed twice with M9 media (minimal media supplemented 
with 1 g/L 15N labeled NH4Cl) before being inoculated into the same media. All 
proteins were purified on Ni-NTA resin (Qiagen), the His-tag removed by TEV 
protease cleavage, followed by further purification. CHIP protein was expressed 
in E. coli (BL21 DE3 LysS) and purified on glutathione sepharose resin (GE 
Healthcare) [39, 40]. The GST-tag was cleaved using PreScission protease (Ge 
Healthcare) and purified prior to use.  
 
4.4.5. Fluorescence quenching assay 
Protein samples were labeled and prepared as previously described [24, 41]. 
Briefly, amine reactive Alex488 (Invitrogen) was used to label Hsp70 and DnaK 
by mixing the dye and protein at a 10:1 molar ratio in bicarbonate buffer (100 mM 
NaHCO3 [pH 8] containing 150mM NaCl). CHIP, HOP, DnaJ, and FKBP51 were 
similarly labeled using BHQ-10 (Biosearch Technologies) at a molar ratio of 50:1, 
dye: protein. Excess labels were removed by passage through ZebaTM desalting 
columns (Thermo Scientific) equilibrated with HEPES-buffered saline (25 mM 
HEPES, 150 mM NaCl [pH 7.4]). Using the extinction coefficients supplied by the 
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manufacturer, label concentrations were determined for each protein sample and 
used to calculate the amount of molar incorporation. MIR values for Hsp70, 
DnaK, HOP, FKBP51, DnaJ and CHIP were 3.2, 2.5, 7.2, 12.1, 17.4 and 14.1 
respectively. All quenching assays were performed at the indicated protein 
concentrations in 50 mM HEPES buffer (pH 7.4) containing 75 mM NaCl, and 
0.05% Tween-20 in a 384-well microplate. Compound or DMSO control was 
administered directly to each well at the indicated concentrations, and the plate 
was incubated at 25°C for 2 hours. Equilibrium binding measurements were 
taken using a SpectraMax M5 microplate reader (Molecular Devices). Each 
sample was excited at 480nm and total fluorescence was read at 525nm with a 
515nm cut-off. The average fluorescence intensity of 15 reads was recorded for 
each sample. In all of these experiments the effect of compound on fluorophore 
fluorescence is controlled for, and compound causes no appreciable change in 
the absorbance spectra of the BHQ-10 quencher (Appendix 4.5.3).   
 
4.4.6. Gel filtration assays 
Purified protein was pre-incubated on ice in HEPES buffered saline (10 mM 
HEPES, 100 mM NaCl, pH 7.4) containing 1 mM ADP and either 500 μM 
compound or DMSO control. Each sample was injected onto an analytical size 
exclusion column (Superdex 200, GE Healthcare) and run at 0.5 mL/min in 
HEPES buffer. All curves were normalized to the elution peak of free nucleotide 
using GraphPad Prism 4.0.  
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4.4.7. ATPase assays  
The colormetric assay for monitoring steady-state ATP activity has been 
previously described [25, 26]. Briefly, Hsc70 (1 μM) and the J-domain of DnaJ 
(0.2 μM) were prepared in assay buffer (0.02% Triton X-100, 100 mM Tris-HCl, 
20 mM KCl, and 6 mM MgCl2 [pH 7.4]). Protein samples were aliquoted into 96-
well plates containing 1 mM ATP and either compound at the indicated 
concentrations or DMSO control. After 3h at 37°C, malachite green reagent was 
used to detect liberated phosphate and the signal measured on a SpectraMax 
M5. 
 
4.4.8. Plasmids, transfections and co-immunoprecipitation 
The sequences for full length human CHIP (STUB1) HOP (STI1) and FKBP51 
(FKBP5) were cloned into the pKH3 plasmid (kind gift from the Allen Saltiel Lab, 
Michigan). HeLa Cells were seeded at a density of 10,000/cm2 on 10x100 mm 
plates and grown to 80% confluence (3 days). Overnight transfections were 
carried out using Lipofectamine 2000 reagent (Invitrogen) in Opti-MEM media 
(Gibco). Cells were lysed at 4°C with lysis buffer (25 mM Tris, 100mM NaCl, 
1mM EDTA, 1% NP-40, 5% Glycerol, 10mM phenylmethanesulfonylfuoride 
(PMSF) and protease inhibitor cocktail [pH 7.4]). Cleared lysates (3 mg/condition) 
were incubated with Ha-Sepharose (Thermo Fisher) at 4°C overnight. Resin was 
washed twice with TBS (25 mM Tris, 100mM NaCl [pH 7.4]) and eluted with 
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100mM Glycine, pH 2.4 at 25°C for 10 min. Standard western blotting procedures 
were followed to probe for proteins using antibodies towards the Ha-tag and 
Hsc70 (Santa Cruz Biotechnology).  
 
4.4.9. MAPT stability assays 
HeLa cells stably expressing V5-tagged tau (kind gift from Chad Dickey Lab, USF 
[27]) were seeded in 6-well plates at a density of 100,000/well and grown to 60% 
confluence (2 days). On the morning of the 2nd day, cells were treated with the 
indicated concentration of compound, or a DMSO control and incubated at 37°C 
for 5 hours. Cells were lysed at 4°C with M-PER lysis buffer (Thermo Scientific) 
containing 1mM PMSF and protease inhibitor cocktail. Standard western blotting 
procedures were used to probe proteins using antibodies towards β-actin (Santa 
Cruz Biotechnology) and the V5-tag (Sigma Aldrich). 
 
Notes 
The work in this chapter was a collaborative effort, and is in preparation to be 
published under the title “Spergualin analogs as novel inhibitors of the 
Hsp70/CHIP protein-protein interaction”. Matthew Smith and Jason Gestwicki 
designed the experiments. Matthew Smith and Chris Evans synthesized all 
compounds. Matthew Smith performed the experiments. And Matthew Smith and 
Jason Gestwicki wrote the manuscript.  
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4.5. Appendix 
4.5.1. Characterizing Hsc70 PPIs by fluorescence-quenching assay 
 
  122 








1. Rudiger, S., et al., Substrate specificity of the DnaK chaperone determined 
by screening cellulose-bound peptide libraries. EMBO J, 1997. 16(7): p. 
1501-1507. 
2. Mayer, M. and B. Bukau, Hsp70 chaperones: Cellular functions and 
molecular mechanism. Cellular and Molecular Life Sciences, 2005. 62(6): 
p. 670-684. 
3. Kampinga, H.H. and E.A. Craig, The HSP70 chaperone machinery: J 
proteins as drivers of functional specificity. Nature Reviews Molecular Cell 
Biology, 2010. 11(8): p. 579-592. 
4. Szabo, A., et al., The ATP hydrolysis-dependent reaction cycle of the 
Escherichia coli Hsp70 system DnaK, DnaJ, and GrpE. Proceedings of the 
National Academy of Sciences, 1994. 91(22): p. 10345-10349. 
5. McCarty, J.S., et al., The Role of ATP in the Functional Cycle of the DnaK 
Chaperone System. Journal of Molecular Biology, 1995. 249(1): p. 126-
137. 
6. Allan, R.K. and T. Ratajczak, Versatile TPR domains accommodate 
different modes of target protein recognition and function. Cell Stress & 
Chaperones, 2011. 16(4): p. 353-367. 
7. Kettern, N., et al., Chaperone-assisted degradation: multiple paths to 
destruction. Biological Chemistry, 2011. 391(5): p. 481-489. 
8. Scheufler, C., et al., Structure of TPR Domain-Peptide Complexes: Critical 
Elements in the Assembly of the Hsp70-Hsp90 Multichaperone Machine. 
Cell, 2000. 101(2): p. 199-210. 
9. Zeytuni, N. and R. Zarivach, Structural and Functional Discussion of the 
Tetra-Trico-Peptide Repeat, a Protein Interaction Module. Structure, 2012. 
20(3): p. 397-405. 
10. Grove, T.Z., A.L. Cortajarena, and L. Regan, Ligand binding by repeat 
proteins: natural and designed. Current Opinion in Structural Biology, 
2008. 18(4): p. 507-515. 
11. Miyata, Y., et al., Molecular chaperones and regulation of tau quality 
control: strategies for drug discovery in tauopathies. Future Medicinal 
Chemistry, 2011. 3(12): p. 1523-1537. 
12. Kundrat, L. and L. Regan, Balance between Folding and Degradation for 
Hsp90-Dependent Client Proteins: A Key Role for CHIP. Biochemistry, 
2010. 49(35): p. 7428-7438. 
13. Yi, F. and L. Regan, A Novel Class of Small Molecule Inhibitors of Hsp90. 
Acs Chemical Biology, 2008. 3(10): p. 645-654. 
14. Ardi, V.C., et al., Macrocycles That Inhibit the Binding between Heat 
Shock Protein 90 and TPR-Containing Proteins. Acs Chemical Biology, 
2011. 6(12): p. 1357-1366. 
15. Takeuchi, T., et al., A new antitumor antibiotic, spergualin: isolation and 
antitumor activity. J Antibiot (Tokyo), 1981. 34(12): p. 1619-21. 
  125 
16. Umezawa, H., et al., Structure of an antitumor antibiotic, spergualin. J 
Antibiot (Tokyo), 1981. 34(12): p. 1622-4. 
17. Iwasawa, H., et al., Synthesis of (-)-15-deoxyspergualin and (-)-
spergualin-15-phosphate. J Antibiot (Tokyo), 1982. 35(12): p. 1665-9. 
18. Dickneite, G., et al., 15-deoxyspergualin: from cytostasis to 
immunosuppression. Behring Inst Mitt, 1988(82): p. 231-9. 
19. Amemiya, H., et al., A NOVEL RESCUE DRUG, 15-DEOXYSPERGUALIN 
- 1ST CLINICAL-TRIALS FOR RECURRENT GRAFT-REJECTION IN 
RENAL RECIPIENTS. Transplantation, 1990. 49(2): p. 337-343. 
20. Nadler, S., et al., Interaction of the immunosuppressant deoxyspergualin 
with a member of the Hsp70 family of heat shock proteins. Science, 1992. 
258(5081): p. 484-6. 
21. Nadler, S., et al., Identification of a binding site on Hsc70 for the 
immunosuppressant 15-deoxyspergualin. Biochem Biophys Res Commun, 
1998. 253(1): p. 176-80. 
22. Nadeau, K., et al., Quantitation of the interaction of the 
immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. 
Biochemistry, 1994. 33(9): p. 2561-7. 
23. Brodsky, J., Selectivity of the molecular chaperone-specific 
immunosuppressive agent 15-deoxyspergualin: modulation of Hsc70 
ATPase activity without compromising DnaJ chaperone interactions. 
Biochem Pharmacol, 1999. 57(8): p. 877-80. 
24. Chang, L., et al., Chemical Screens against a Reconstituted Multiprotein 
Complex: Myricetin Blocks DnaJ Regulation of DnaK through an Allosteric 
Mechanism. Chemistry &amp; Biology, 2011. 18(2): p. 210-221. 
25. Miyata, Y., et al., High-Throughput Screen for Escherichia coli Heat Shock 
Protein 70 (Hsp70/DnaK): ATPase Assay in Low Volume by Exploiting 
Energy Transfer. Journal of Biomolecular Screening, 2010. 15(10): p. 
1211-1219. 
26. Chang, L., et al., High-throughput screen for small molecules that 
modulate the ATPase activity of the molecular chaperone DnaK. Analytical 
Biochemistry, 2008. 372(2): p. 167-176. 
27. Dickey, C., et al., Akt and CHIP coregulate tau degradation through 
coordinated interactions. Proc Natl Acad Sci U S A, 2008. 105(9): p. 3622-
7. 
28. Dickey, C., et al., The high-affinity HSP90-CHIP complex recognizes and 
selectively degrades phosphorylated tau client proteins. J Clin Invest, 
2007. 117(3): p. 648-58. 
29. Umeda, Y., et al., Synthesis and antitumor activity of spergualin 
analogues. II. Chemical modification of the spermidine moiety. J Antibiot 
(Tokyo), 1987. 40(9): p. 1303-15. 
30. Kamiguchi, K., et al., Disruption of the association of 73 kDa heat shock 
cognate protein with transporters associated with antigen processing 
(TAP) decreases TAP-dependent translocation of antigenic peptides into 
  126 
the endoplasmic reticulum. Microbiology and Immunology, 2008. 52(2): p. 
94-106. 
31. Amemiya, H., et al., MULTICENTER CLINICAL-TRIAL OF 
ANTIREJECTION PULSE THERAPY WITH DEOXYSPERGUALIN IN 
KIDNEY-TRANSPLANT PATIENTS. International Journal of Clinical 
Pharmacology Research, 1991. 11(4): p. 175-182. 
32. Yutaka, M., H. Quazi Manjurul, and N. Shusuke, Inhibition of Malaria-
Infected Erythrocytes by Deoxyspergualin: Effect on in vitro Growth of 
Malarial Cultures. Chemotherapy, 1998. 44(6): p. 409. 
33. Nishikawa, K., et al., Antitumor activity of spergualin, a novel antitumor 
antibiotic. J Antibiot (Tokyo), 1986. 39(10): p. 1461-6. 
34. Umezawa, K. and T. Takeuchi, Spergualin: a new antitumour antibiotic. 
Biomed Pharmacother, 1987. 41(5): p. 227-32. 
35. Evans, C., et al., Improved synthesis of 15-deoxyspergualin analogs using 
the Ugi multi-component reaction. Bioorg Med Chem Lett, 2011. 
36. Feichtinger, K., Zapf, C., Sings, H.L., and Goodman, M., Diprotected 
Triflylguanidines: A New Class of Guanidinylation Reagents. J Org Chem, 
1998. 63(12): p. 3804-05. 
37. Xu, P.Z., Ting; Wang, Wenhao; Zou, Xiaomin; Zhang, Xin; Fu, Yiqiu, 
Synthesis of PNA Monomers and Dimers by Ugi Four-Component 
Reaction. Synthesis, 2003. 2003(8): p. 1171-76. 
38. More, J.D. and N.S. Finney, A Simple and Advantageous Protocol for the 
Oxidation of Alcohols with o-Iodoxybenzoic Acid (IBX). Org Lett, 2002. 
4(17): p. 3001-3003. 
39. Scaglione, K.M., et al., Ube2w and Ataxin-3 Coordinately Regulate the 
Ubiquitin Ligase CHIP. Molecular Cell, 2011. 43(4): p. 599-612. 
40. Brzovic, P.S., et al., A UbcH5/ubiquitin noncovalent complex is required 
for processive BRCA1-directed ubiquitination. Molecular Cell, 2006. 21(6): 
p. 873-880. 
41. Ruan, Q., J. Skinner, and S. Tetin, Using nonfluorescent Forster 
resonance energy transfer acceptors in protein binding studies. Anal 








Conclusions and future directions 
 
5.1. Abstract 
There are an estimated 600,000 protein-protein interactions (PPIs) in any given 
cell, which help to facilitate virtually every cellular function. From a therapeutic 
perspective, this observation presents a massive untapped opportunity for novel 
intervention in previously intractable diseases, such as some types of cancer and 
neurodegeneration. As discussed in Chapter 1, the challenges of developing 
small molecule modulators of these PPIs are significant, but they can sometimes 
be surmounted with the right tools and strategies. PPIs in protein quality control 
have been of particular interest to chemical biologists and, in this thesis, I have 
described one successful example of targeting a critical quality control PPI. The 
rational design approach we took is one of many avenues available for advancing 
a drug target campaign against a PPI. In this chapter, I expand upon the possible 
uses for the spergualin analogs that have already been characterized, as well as 
provide a framework for further improvement of these compounds, both in terms 




5.2.1. Targeting protein quality control using small molecules: Rationale for 
targeting the Hsp70-CHIP interface 
The Lasker Prize in 2011 was awarded to Hartl and Horwich for their work on the  
discovery that many cellular proteins require the assistance of molecular 
chaperones to be properly folded [1]. Most molecular chaperones drive this 
process using ATP hydrolysis. For example, heat shock protein 70 (Hsp70) uses 
ATPase activity to regulate its binding to hydrophobic residues in substrate 
proteins (Figure 5.1). Through these activities, Hsp70 is well positioned as a key 
component of protein quality control [2]. As discussed extensively in this thesis, 
protein-protein interactions (PPIs) between Hsp70 and the superfamily of co-
chaperones are now believed to be central to guiding the fate of Hsp70-bound 
substrates [3-5] (Figure 5.1). However, to date there are few examples of small 
molecules that are able to manipulate PPIs in the Hsp70 complex. It is likely that 
a more complete series of such chemical probes would be invaluable in better 
understanding chaperone biology and its roles in disease.  
 
In Chapter 2, I described the characterization of the PPI between Hsp70 and the 
TPR (tetratricopeptide repeat) co-chaperone CHIP (C-terminus of Hsc70 
interacting protein). There we reported that the interaction between the TPR of 
CHIP and the C-terminal domain from Hsp70 constitute ~80% of the binding 
affinity for these two proteins. With so much of the binding energy focused on this 
  129 
discrete interaction, we hypothesized that a small molecule binding to this region 
would be able to inhibit this PPI. Additionally, since CHIP essentially links Hsp70 
and its clients to the proteasome by its ubiquitin ligase activity [6], modulation of 
the Hsp70-CHIP interaction could have wide ranging effects on protein quality 
control within the cell.  
 
5.2.2. Summary of major advances and characterization of spergualin 
analogs as inhibitors of the Hsp70-CHIP PPI 
In Chapter 3, I describe work aimed at expanding access to an interesting class 
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of compounds based on the natural product, spergualin. This scaffold was 
suggested to bind to the C-terminus of the constitutively expressed Hsc70 [7]. 
The rationale for redesigning the synthesis was to gain improved access to this 
compound and its derivatives, in order to test whether they inhibit the Hsp70-
CHIP PPI. The resulting synthetic route had an ~5-fold better overall yield 
compared to the previously published routes [8], constituting a major advance in 
the synthesis of these compounds. Moreover, due to the modular nature of our 
synthetic scheme, we were able to rapidly assemble new analogs.  
 
Using our improved synthesis, we designed a small library of spergualin 
derivatives with a focus on modification at the 11-position [9]. And, in Chapter 4, I 
provide the first evidence that these compounds inhibit the PPI between Hsp70 
and TPR proteins (Figure 5.2). Furthermore, we found that these compounds 
increased the levels of the Hsp70-CHIP client, tau, suggesting that spergualin 
analogs could indeed alter cellular quality control. This novel activity for the 
spergualin scaffold provides an exciting, new tool for exploring the biology of 
Hsp70-TPR protein interactions. For example, recent evidence suggests that 
CHIP may play a role in peptide presentation by the major histocompatibility 
complex (MHC) class 1 [10]. These results may help explain why spergualin 
analogs have  immunosuppressive activity.  
 
The work described here provides important new insight into the nature of the 
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Hsp70-CHIP interaction and produced the first chemical probes of this contact. 
However, there are a number of important questions related to the mechanism of 
action of these compounds. Answers to these questions will be important in 
further advancing this chemical series for use as research reagents and, 
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potentially, as therapeutics.  
 
5.3. Future directions 
5.3.1. Improving potency and building selectivity 
As discussed in Chapter 3, the most likely binding site for spergualin is the Hsc70 
EEVD motif [11]. However, there is little characterization of this possible binding 
mode. In Chapter 4, I describe our efforts to re-investigate the mechanism of 
binding for our spergualin derivatives using NMR, but these studies are in their 
preliminary stages. Once the binding site is mapped, molecular modeling can be 
used to predict the key regions of the spergualin scaffold that are important. With 
this information, structure-guided medicinal chemistry might be used to optimize 
the ligand binding efficiency and increase its affinity. In the absence of binding 
information, a large-scale spergualin library, with enough variability, could 
potentially lead us to a more potent compound, and a mixture of these two 
approaches will likely be the most efficient way forward. Questions of particular 
interest include: is the polyamine required for membrane permeability? How 
much steric bulk is tolerated at the 11 position? Which areas of the molecule 
remain as major metabolic liabilities and how can these be fixed?  
 
The next major question facing this project is whether the spergualin scaffold can 
be adjusted to gain selectivity for different members of the TPR co-chaperone 
superfamily. This is an important goal because different TPR proteins, such as 
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CHIP and HOP, produce opposing outcomes for some Hsp70 substrates. 
However, the spergualin analogs produced thus far do not distinguish between 
these TPR domains. The best chance of building selectivity might be to 
determine the binding mode, so that we could take advantage of structural 
differences that exist between the different TPR domains [12, 13]. For instance, a 
brief analysis reveals that there are interactions in the Hsp70-HOP complex that 
are not present between Hsp70-CHIP (Figure 5.3). We may be able to gain 
selectivity by building substitutions within the spergualin scaffold that are 
sensitive to these differences.  
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A related concern arises from the fact that Hsp90 uses the same C-terminal 
EEVD motif to bind to TPR proteins [12]. Since spergualin has been 
characterized as binding Hsp90 as well [14], this suggests that spergualin 
analogs may also inhibit the Hsp90-TPR PPI (Appendix 5.4.1). In a similar 
fashion to installing selectivity between TPR proteins of the Hsp70 interaction, we 
could take advantage of the structural differences between Hsp70 and Hsp90 
binding to the TPR. These differences are well illustrated by HOP, where the 
chaperones bind to separate TPR domains of the same protein, using distinct 
binding modes [12].  
 
5.3.2. Re-exploring the therapeutic potential of spergualins 
Like many natural products, spergualin was first characterized as having a 
number of different biological activities. Originally, the molecule was labeled as 
an antitumor antibiotic [15], owing to its activity against both gram-positive and 
gram-negative bacterial strains [16]. In addition, these compounds have anti-
proliferative activity in tumor models [17]. Soon after, the potent 
immunosuppressive activity of the scaffold was discovered and the analog, 15-
DSG, was approved for acute allograft rejection in Japan [18, 19]. More recently, 
spergualin has been shown to be effective in treating the more chronic condition 
of graft versus host disease (GVHD) [20], and it also shows activity in 
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suppressing malarial infection [21]. One looming, fundamental question is how 
this simple molecule could achieve such divergent, and often potent, activities.  
 
One possible explanation may be found in spergualin's target molecule. Hsp70 
has been shown to play critical roles across cellular pathways and it has been 
implicated in many different diseases. Thus, the spergualin scaffold may provide 
an unbiased chemical probe for better understanding the link between Hsp70 and 
the diseases mentioned here. In this search, combining spergualins with 
proteomic techniques, such as mass spectral analysis, might be used to monitor 
changes in genome-wide protein stability. This type of analysis would provide a 
roadmap to understanding how this molecule broadly effects Hsp70-TPR-
substrate multi-protein complexes within the cell, and would allow us to 
retrospectively piece together a mechanistic understanding of spergualin's effect 
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Neurodegenerative disorders such as Alzheimerʼs and Huntington's disease, all 
display the hallmark aggregation of misfolded proteins. Yet it remains unknown 
how this aggregation process contributes to disease. Recent studies suggest that 
the sequestration of small aggregates into larger, centralized deposits 
(aggresomes) may be a novel mechanism in protein quality control (PQC). In this 
Appendix, I focus on one of the key components of PQC, heat shock protein 70 
(Hsp70) and explore how protein-protein interactions in the Hsp70 system effect 
in vivo protein aggregation and aggresome formation in the model organism 
Saccharomyces cerevisiae. Our preliminary results suggest that aggresome 
formation increases the longevity of cells harboring a heavy aggregate burden. 
Furthermore, inhibition of this process, either by stimulating the Hsp70-Hsp40 
interaction or inhibiting interactions between Hsp70 and tetratricopeptide repeat 
(TPR) proteins, has a negative effect on longevity. These data provide support 
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for the role aggresome formation plays in PQC and suggest that aggresomes 
may be a mechanism by which cells cope with misfolded protein in 
neurodegeneration. 
 
A.1.1. Protein aggregation in neurodegeneration 
Research into neurodegeneration started over 100 years ago when Alois 
Alzheimer described a proteinacious deposition in and around neurons of 
patients suffering from dementia [1, 2]. Since then, scientists have uncovered 
several diseases that are symptomatically distinct from Alzheimer's case, yet 
share this characteristic protein aggregation in neuronal cells [3]. Why proteins 
preferentially aggregate in these disease states and how this aggregation 
process contributes to the degeneration of neurons are key questions in the field. 
Recent studies have advanced the notion that small, soluble oligomers of 
misfolded protein represent a toxic aggregation species, while larger, insoluble 
deposits are relatively benign [4-6]. This is supported by the observation that 
protein deposition in humans does not correlate with disease severity [7]. 
Interestingly, Ron Kopito and colleagues have recently identified a form of 
aggregation that is facilitated by the cell, essentially sequestering distal 
aggregates into a large, centralized deposit that can be cleared through 
autophagy [8-11]. These deposits have been termed aggresomes and may 
represent a novel mechanism for eliminating misfolded protein from the cytosol 
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[12, 13]. However, to what extent is this novel process integrated into the well 
established protein quality control (PQC) system? Additionally, what role might 
aggresomes play in neurodegeneration? In this Appendix, I explore these 
questions using Saccharomyces cerevisiae as an in vivo model of protein 
aggregation.  
 
A.1.2. Aggresome formation and protein quality control 
As discussed previously in my thesis, major components of the PQC system 
include heat shock protein 70 (Hsp70), Hsp90, Hsp40, nucleotide exchange 
factors (NEFs), and tetratricopeptide repeat (TPR) domain proteins [14]. Protein-
protein interactions (PPIs) within this system facilitate the folding or degradation 
of misfolded substrates in an ATP-dependent manner [14]. Both Hsp70 and 
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Hsp90, along with several other PQC components, have been shown to co-
localize to the aggresome by immunofluorescent staining [15]. Also, as in the 
process of proteasomal degradation, ubiquitination appears to be an essential 
initiator of aggresome formation [13, 16]. In fact, proteasomal inhibition increases 
aggresome formation in cells expressing misfolded proteins [17, 18], suggesting 
that aggresomes may compensate for decreased proteasome function. Finally, 
once formed, aggresomes are engulfed by autophagosomes and cleared from 
the cytosol [10, 11]. Based on these data, we hypothesize that aggresomes are 
an integrated part of PQC, allowing misfolded proteins to be detoxified through 
sequestration into a benign deposit and eventually removed from the cell by 
autophagy. The preliminary results presented in this appendix provide a basis for 
speculation on the connection between aggresome formation and PQC and 
generate hypotheses for future study. 
 
A.2. Results 
A.2.1. A Saccharomyces cerevisiae model of aggresome formation 
Exon 1 of the Huntingtin (Htt) gene harbors a CAG repeat region that encodes a 
string of consecutive glutamines in the resulting protein [19]. Longer repeat 
regions lead to higher instability of the protein, the increased propensity for 
aggregation and a greater severity and earlier onset of symptoms of Huntington's 
disease (Figure A.1). Huntingtin expression causes the formation of aggresomes 
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in eukaryotic cells [20], and the concomitant inhibition of proteasomal 
degradation [21, 22], as seen in the disease. Baker's yeast (Saccharomyces 
cerevisiae) offers a convenient way to model the expression of huntingtin 
aggresome formation in vivo [23, 24]. In this study we use yeast harboring 
chromosomal insertions of CFP (cyan fluorescent protein)-fused human Htt exon 
1 with 103 (Q103) glutamine repeats, which is prone to rapid aggregation. and  
soluble CFP-fused human Htt exon 1 containing  25 glutamine repeats (Q25) as 
a control [25]. Both insertions were made under the GAL promotor and thus 
expression of the transgene is sensitive to the yeast carbon source.  
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A.2.2. Modulation of the Hsp70-Hsp40 interaction inhibits aggresome 
formation 
Twenty-four hours after induction, the majority of yeast expressing Q103 form 
aggresomes (represented by a single, intracellular puncta; Figure A.2A). In cells 
expressing Q25, the mutant protein remains soluble. The dihydropyrimidine 
SW02 has been shown to selectively stabilize the interaction between Hsp70 and 
the J-domain of Hsp40, leading to the stimulation of ATPase activity [26]. As the 
first step in recognition of misfolded proteins is likely binding to Hsp70, we used 
this compound to test whether modification of the Hsp70-Hsp40 PPI affects 
aggresomes. Yeast treated with SW02 during the first 24 hours of Q103 induction 
show a marked decrease in aggresome formation, as measured by the number 
of cells that form these single puncta (Figure A.2A). Conversely, addition of 
SW02 after aggresome formation, has no effect (data not shown). This finding 
suggests that aggresome formation is dependent on PPIs within the PQC 
system, and can therefore be considered as part of PQC.  
 
A.2.3. The pharmacological inhibition of aggresome formation is persistent 
over time 
We next wanted to see how aggregation is manifest in the yeast cell over time. 
Cells were left to grow for the indicated times in induction media and then imaged 
for expression of mutant CFP-Htt protein. Interestingly, as the culture aged, the 
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number of Q103 cells that formed aggresomes increased as a function of the 
total number of live cells (Appendix A.5.1). This suggests that aggresome 
formation may give the cell a competitive advantage for survival. Treatment with 
SW02 during the first 24 hours of induction had a sustained inhibitory effect on 
the formation of aggresomes (compare Figure A.3A and B). The carbon source 
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is likely exhausted within the first 24 hours, so the aggregation pattern shown in 
these results is likely due the initial inhibition of aggresome formation, and not a 
persistent effect of the compound, as no new Q103 Htt is produced.  
 
A.2.4. Inhibiting aggresome formation decreases cellular longevity 
Since cells treated with SW02 in the first 24 hours do not seem to regain the 
ability to sequester mutant Q103 Htt into an aggresome, we next sought to 
determine the effect this might have on cell survival. In order to do this, we took 
advantage of the stationary phase model of yeast aging. In these experiments, 
liquid cultures are maintained in a non-fermenting state, past logarithmic growth. 
A known number of yeast are periodically removed from liquid culture and re-
grown on solid media. Survival is measured as the number of individual colonies 
produced as a function of time. To our surprise, yeast expressing Q103 protein 
tended to have a significantly more robust lifespan compared to their 
counterparts expressing the soluble Q25 (Figure A.4A). This effect can also be 
seen by taking yeast at the end of the lifespan curve (Day 12) and inoculating 
fresh liquid media. Q103 cells show higher levels of growth than Q25 at this late 
time-point (Figure A.4B), suggesting that there are more live cells in Q103 
available to inoculate the culture. One possible confounding explanation for this 
is that expression of Q103 Htt reduces the metabolism in these cells [27], and 
thereby causes an increase in longevity. Regardless, treatment with SW02 during 
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the first 24 hours of induction negates this beneficial effect on longevity, 
producing no difference between the survival of Q25 and Q103 treated cells 
(Figure A.4C). This result suggests that inhibiting aggresome formation is toxic 
to cells, and is supportive of the literary notion that aggresomes are beneficial. An 
interesting aside for this thesis is that the spergualin analog MeDSG, described in 
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Chapter 3, also causes a decrease in aggresome formation (Figure A.5). This 
result implicates a potential role for TPR proteins in the initiation of aggresomes.  
 
A.3. Conclusions 
A.3.1. Aggresome formation facilitates cell survival during high misfolded 
protein burden 
Several studies have characterized the presence of aggresomes in various 
models of neurodegeneration [20, 28-32]. The current view is that these 
structures are a staging area to both accumulate misfolded protein, thereby 
sequestering it away from the rest of the proteome, and eventually dispose of it 
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[8]. Our data are supportive of this hypothesis, as we found that long-lived cells 
expressing misfolded protein tend to harbor aggresomes and acute inhibition of 
aggresome formation has a toxic effect on the longevity of these cells.  
 
A.3.2 Protein quality control directs the formation of aggresomes 
One way to identify aggresomes and to distinguish them from other forms of 
protein aggregates is to monitor co-localization with a number of PQC 
components [13, 22, 29, 33, 34]. This, together with genetic studies showing the 
importance of Hsp70 and Hsp90 in aggresome formation [35] led us to the 
hypothesis that aggresomes may be controlled by the PQC system. The data 
presented here suggest that this may be the case, since stimulating the Hsp70-
Hsp40 interaction causes a reduction in aggresomes. Interestingly, Hsp40-
mediated ATP hydrolysis causes Hsp70 to bind substrate proteins with high 
affinity. This high affinity Hsp70-substrate complex also shows resistance to 
clearance through the proteasome [36], perhaps representing a situation in which 
substrates are transiently “stuck” in the Hsp70 binding cycle. Although our results 
begin to suggest a mechanism of how Hsp70 may help regulate aggresome 




A.4. Materials and methods 
A.4.1. General materials 
All yeast strains expressing the Huntingtin fusions were a kind gift from the 
Martin Duennwald lab (Boston Biomedical Research Institute). SW02 [26] and 
MeDSG (Chapter 3) were synthesized in-house according to previously 
described procedures.  
 
A.4.2. Yeast growth and induction 
All cells were routinely cultured at 30°C on selective SD medium before being 
transferred to liquid SG medium (containing drug or DMSO control) for induction 
of Q25 or Q103 expression.  
For live-dead analysis of yeast by microscopy, 50 μL of cells was harvested from 
liquid culture, washed with phosphate buffered saline [pH 7] (PBS) and incubated 
with 0.05 mg/mL of propridium iodide (Sigma Aldrich) in PBS for 10 min at room 
temperature. Live cells were then immobilized on Concanavalin A coated 
coverslips, mounted on slides and imaged.  
 
A.4.3. Yeast aging assay 
Standard protocols for measuring chronological aging in stationary phase yeast 
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cultures were employed throughout this study [37]. Briefly, single colonies were 
inoculated into SD media and grown overnight. Total liquid cultures were then 
washed with sterile PBS and inoculated into 20 mL SG media to a normalized 
OD600 value of 0.2 (media contains either the indicated concentration of 
compound or DMSO as a control). Yeast were grown at 30°C with 200 rpm 
shacking and at the indicated time-points, 10 μL of the liquid culture was diluted 
to reach 1:10^4 dilution in sterile water. 10 μL of this dilution was plated onto 
solid SD media and grown for 2 days. Single colonies formed were counted, with 
the number recorded at the first time-point representing 100% survival.  
 
A.4.4. Fluorescence microscopy 
Microscopy was performed using an Eclipse 80i system (Nikon Corporation) with 
DIC, CFP and TRITC filters. All images were processed using Metamorph 
analysis software (Molecular Devices).  
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